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CHAPTER 1 
1.INTRODUCTION 
 
Complementary Alternative System of Medicine 
 There is new life in the soil for every man. There is healing in the trees for 
tired minds and for our overburdened spirits, there is strength in the leafs, if only 
we will lift up our eyes. Remember that nature is your great restorer. 
 Herbal medicine -- also called botanical medicine or phytomedicine , 
refers to using plant’s seeds, berries, roots, leaves, bark or flowers for medicinal 
purposes. Herbalism has a long tradition of use outside of conventional 
medicine[26]. It is becoming more main stream as improvements in analysis and 
quality control along with advances in clinical research show the value of herbal 
medicine in treating and preventing disease. 
 
 
  
 
   
 Plants had been used for medicinal purposes long before. Ancient Chinese 
and Egyptian papyrus writings describe medicinal uses for plants. Indigenous 
cultures (such as African and Native American) used herbs in their healing rituals, 
while others developed traditional medical systems (such as Ayurveda and 
Traditional Chinese Medicine) in which herbal therapies were used. Researchers 
found that people in different parts of the world tend to use the same or similar 
plants for the same purposes. 
Introduction  
 
‐2‐ 
 
 In the early 19th century, when chemical analysis first became available, 
scientists began to extract and modify the active ingredients from plants. Later, 
chemists began making their own version of plant compounds and over time, the 
use of herbal medicines declined in favor of drugs. 
 Recently, the World Health Organization estimated that 80% of people 
worldwide rely on herbal medicines for some part of their primary health care. In 
Germany, about 600 - 700 plant-based medicines are available and are prescribed 
by some 70% of German physicians[24]. In the last 20 years in the United States, 
public dissatisfaction with the cost of prescription medications, combined with an 
interest in returning to natural or organic remedies, has led to an increase in herbal 
medicine use. 
 The use of herbal supplements has increased dramatically over the past 30 
years. Herbal supplements are classified as dietary supplements by the U.S. 
Dietary Supplement Health and Education Act (DSHEA) of 1994[25]. That means 
herbal supplements -- unlike prescription drugs -- can be sold without being tested 
to prove that they are safe and effective. However, herbal supplements must be 
made according to Good Manufacturing Practices. 
 Herbs may be used together because the combination is more effective and 
may have fewer side effects. Health care providers must take many factors into 
account when recommending herbs, including the species and variety of the plant, 
the plant's habitat, how it was stored and processed and whether or not there are 
contaminants (including heavy metals and pesticides). 
 Nearly one-third of Americans use herbs. Unfortunately, a study in the 
New England Journal of Medicine found that nearly 70% of people taking herbal 
medicines (most of whom were well educated and had a higher-than-average 
income) were reluctant tell their doctors that they used complementary and 
alternative medicine[27]. 
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Complementary Alternative System of Medicine 
 Alternative medicine is a set of diverse traditional medicinal health care 
systems and practices that are not generally considered as part of conventional or 
modern medicine. 
 Alternative medicine is a health care approach that is applied instead of 
Conventional or Western medicines. Alternative medicinal treatment may include 
ingesting or applying organic substances (mostly herbs and some minerals) with a 
special diet plan (mostly vegetables and fruits), that are not normally advised by a 
physician who practices conventional or modern medicines[33]. The alternative 
medicines are not only providing treatment for any health condition but also guide 
us for how to live a healthier life. 
Alternative medicine user’s statistics 
 Survey results released in May 2004 by the National Center for 
Complementary and Alternative Medicine (NCCAM) and the National Center for 
Health Statistics (part of the Centers for Disease Control and Prevention) shows in 
the United States alone, approximately 36% of adults used some form of CAM 
therapy during the past 12 months. 
 British telephone survey by the BBC in 1998 shows about 20% of adults 
had used alternative medicine in the past 12 months. 
 Use of alternative medicine among people in developed countries appears 
to be increasing. A study in 1998 showed that the use of alternative medicine had 
risen from 33.8% in 1990 to   42.1% in 1997. 
 Most commonly practiced complementary treatments include: herbalism, 
yoga, homeopathy, acupuncture/acupressure, meditation, massage, therapeutic 
touch, aroma therapy, Chinese medicine, dance therapy, music therapy, 
osteopathy, chiropractic, and naturopathy. 
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 A 2002 survey of US adults 18 years and older conducted by the National 
Center for Health Statistics (CDC) and the National Center for Complementary 
and Alternative Medicine indicated that 49.8% had used some form of CAM[35]. 
 A survey in 2005 among Denmark population aged 16 and above shows 
45.2 % of them used alternative medicine of form in their life. 22.5 % had used 
alternative medicine within lost 12 months. 
 Patients are averse to dangerous side effects of conventional medicines, 
even antibiotic medications can have potential to cause life-threatening severe 
allergic reaction in a very few individuals. Also, many medications may cause 
minor but troublesome symptoms such as cough or stomach upset. In all of these 
cases, patients are seeking out alternative medicine treatments to avoid these 
adverse side effects of modern treatments. 
 NCCAM has developed one of the most widely used classification systems 
for the branches of complementary and alternative medicine. It classifies 
complementary and alternative therapies into five major groups, which have some 
overlap[34]. 
1. Whole medical systems: cut across more than one of the other groups; 
examples include Traditional Chinese medicine Naturopathy, 
Homeopathy, and Ayurveda 
2. Mind-body medicine: takes a holistic approach to health that explores the 
interconnection between the mind, body, and spirit. It works under the 
premise that the mind can affect "bodily functions and symptoms" 
3. Biology-based practices: use substances found in nature such as herbs, 
foods, vitamins, and other natural substances 
4. Manipulative and body-based practices: feature manipulation or movement 
of body parts, such as is done in chiropractic and osteopathic manipulation 
5. Energy medicine: is a domain that deals with putative and verifiable 
energy fields:  
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1. Traditional Indian Medicine 
 The word Ayurveda is derived from ‘Ayur’, meaning life, and ‘veda’, 
meaning knowledge. Ayurveda means the science of life[28]. It is an ancient 
system of health care and longevity. Ayurveda takes a holistic view of human 
beings, their health and illness. It aims at positive health, which has been defined 
as a well-balanced metabolism coupled with a healthy state of being. Disease, 
according to Ayurveda, can arise from the body and/or mind due to external 
factors or intrinsic causes. 
 Ayurvedic treatment is aimed at the patient as an organic whole and 
treatment consists of the salubrious use of drugs, diet and certain practices. This 
doctrine was conceived when science was not developed enough to understand 
even the human body, let alone drug molecules. 
 Ayurveda, perhaps the most ancient of all medicine traditions, is probably 
older than traditional Chinese medicine. The origin of Ayurveda is lost in 
prehistoric antiquity, but its characteristic concepts appear to have matured 
between 2500 and 500 BCE in ancient India. The earliest references to drugs and 
diseases can be found in the Rigveda and Atharvaveda, dating back to 2000 
BC[31]. Atharvaveda, comprised of 6599 hymns and 700 prose lines, is considered 
as the forerunner of Ayurveda. 
 The ‘Samhitas,’ or encyclopedia of medicine, were written during the 
postvedic era, and include ‘Charak Samhita’ (900 BCE), ‘Sushruta Samhita’ (600 
BC) and ‘Ashtang Hridaya’(1000 BC). Later on, many more treatises were 
prepared and the use of medicinal plants is described in ‘Nighantu Granthas’ 
between the 7th and 16th centuries. The most basic concept of Ayurveda is that all 
living beings derive their subsistence from three essential factors (three doshas), 
namely vaata, pitta and kapha, which operate in unison. It believes that the human 
body is composed of living and non-living environments including earth, water, 
fire, air and space. Illness is the consequence of imbalance between the various 
elements, and it is the goal of treatment to restore this balance. 
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 Ayurvedic drugs are also attracting much attention for diseases for which 
there are no or inadequate drugs for treatment in modern medicine, such as 
metabolic and degenerative disorders[29]. Most of these diseases have 
multifactorial causation, and there is a growing realization that in such conditions, 
a combination of drugs, acting at a number of targets simultaneously, is likely to 
be more effective than drugs acting at one target. 
 Ayurvedic drugs, which are often multicomponent, have a special 
relevance for such conditions. For various reasons, Ayurveda has not incorporated 
much of modern science / scientific tools. Investigation of the biological activity 
of multicomponent. Ayurvedic drugs will bring Ayurveda into the mainstream of 
scientific investigations. 
2. Traditional Chinese Medicine 
 Traditional Chinese medicine (TCM) has been in practice for more than 
200 years and includes acupuncture, massage (tuina), breathing exercise (qi gong) 
and dietary therapy. TCM has been an integral part of China’s healthcare system 
along with conventional Western medicine. TCM products were safe and effective 
for the treatment of many human diseases before Western medicine was 
introduced in China. Famous texts in TCM include the Yellow Emperor’s Inner 
Classic (Hung Di Nei Jing; ~200 BCE to 100 BCE), Divine Husband-man’s 
Classic of Materia Medica (Shen Nong Ben Cao Jing; 25-220 AD) and cold-
induced disorders (Shang han Lun; 220 AD). 
 The most complete reference to Chinese herbal prescriptions is Chinese 
Materia Medica, published in 1977. It lists nearly 6000 drugs, of which 480 are of 
plant origin. This ancient system of medicine, believed to be more than 5000 years 
old, is based on two separate theories about the natural laws that govern good 
health and longevity, namely ‘Yin and Yang’, which are in opposition to each 
other, and the five elements (wu xing). 
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 The five-element theory is similar to the four humours and elements of the 
Greeks or the three humours of Ayurveda. The five elements are earth, metal, 
water, wood and fire, each of which is linked to the main organ systems of the 
body—spleen, lungs, kidney, liver and heart, respectively. It considers that an 
unbalanced diet, lifestyle or environment will disrupt the body balance, which in 
turn manifests as symptoms of diseases[29]. The aim of the practitioner of TCM is 
to restore health by removing the cause, correcting abnormal functioning, 
opposing the imbalance and normalizing the flow of energy. Angelica polymorpha 
var. sinensis, Artemesia annua, Ephedra sinica, Paeonia lactiflora, Panax 
ginseng, Rheum palmatum and Peuraria lobata constitute the important medicinal 
plants of TCM. 
3. Traditional Egyptian Medicine 
 Although Egyptian medicine dates from at least 3000 BCE, the last known 
and most important pharmaceutical record is the Papyrus Ebers (1500 BCE). Use 
of Ricinus communis seeds, Citrilus colocynthes, Senna alexandrina and Prunica 
granatum roots in large quantities is mentioned in the ancient Egyptian literature. 
These uses were later documented by the Greek physician Dioscorides (100 CE). 
Writings of the Greeks, such as Hippocrates (460–377 BCE) and Galen (130–200 
CE), also used parts of the Papyrus Ebers. Therefore Greek and ultimately 
modern, medicine has its origin in Egyptian or Nile Valley civilization. 
4. Traditional Arabic Medicine 
 The Babylonians, Assyrians and Sumerians comprise one of the oldest 
civilizations and several plants were domesticated during this early period. 
Several medicinal plants are mentioned in civil laws carved on stone and 
commissioned by the King of Babylon (1700 BCE). The Arabs established 
drugstores in the eighth century, and the Persian pharmacist Avicenna described 
all Greco-Roman medicine in his book Canon of Medicine. This text forms the 
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basis of distinct Islamic healing system known today as Unani-Tibb. Papaver 
somniferum was known to the Sumerians in 4000 BCE as hul gil (joy plant). 
 The most frequently used medicinal plants in the Middle East are: Allium 
cepa, Astracantha gummifera, Carthamus tinctorius, Carum carvi, Ferula 
asafoetida, Lawsonia inermis, Papaver somniferum, Peganum harmala, Prunus 
dulcis, Prunica granatum, Salvadora persica, Senna alexandrina, Sesamum 
indicum, Trachyspermum ammi, Trigonella foenum-graecum and Vitis vinifera. 
5. African, European and Other Traditional Systems of Medicine 
 Africa is considered the cradle of Homo sapiens’ emergence. Though 
traditional African medicine is the oldest and perhaps the most diverse of all 
healthcare systems, detailed documentation on the use of medicinal plants in 
Africa is lacking. With rapid urbanization, traditional oral knowledge is dwindling 
fast, e.g. knowledge of traditional oral knowledge of the Khoisan, the Nguni and 
the Sotho-speaking peoples. Traditional African medicine is holistic, involving 
both body and mind. Famous African medicinal plants include Acaccia senegal 
(source of gum Arabic), Aloe ferox, Aloe vera, Artemisia afra, Asplanthus 
linearis, Boswellia sacra, Catha edulis, Commiphora myrrha, Harpagophytum 
procumbens, and Catharanthus roseus, etc., Like Africa, South American 
countries are also rich in biodiversity and diverse healing cultures, but information 
on the use of medicinal plants is sparse. The famous medicinal plants from this 
region are Cinchona pubescens, Erythroxylum coca, Ilex paraguariensis, 
Paullinia cupana, Spilanthes acmella Uncarina tomentosa. The European healing 
system is believed to have originated with Hippocrates (460–377 BCE) and 
Aristotle (384–322 BCE). Subsequent naturalists like Theophrastus (~300 BCE), 
Dioscorides (100 CE) and the pharmacist Galen (130–200 CE) recorded the use of 
medicinal plants. 
 The philosophy was based on the belief that the body is composed of earth, 
wind, fire and water, similar to the Indian system. The famous book De Materia 
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Medica by the Greek physician Dioscorides was the standard reference in Europe 
for more than 1000 years. The use of herbal teas and decoctions is still very 
popular in Europe, e.g. tea prepared from Humulus lupulus, Rosmarinum 
officinalis, Hypericum perforum and Valeriana officinalis. 
 Though traditional and alternative medicine and its practitioners exist in 
Europe, it is not officially recognized and is punishable under the law in France, 
Italy, Spain and other countries, while it is unregulated in UK. This requires 
provisions in pharmacopoeias to include herbal drugs. Allopathic medicine is 
practiced predominantly in developed countries, and herbal drugs are categorized 
as food supplements and are not reimbursed by the social security system. 
ANCIENT SYSTEM OF MEDICINE IN INDIA 
   The two Ancient Medicinal systems 
   Ancients system of medicine types  
 
 
 
     Figure-2  
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Sidha System of Medicine 
 Sidha system developed with the   ancient civilizations of Harrappa and 
Mohenjo-daro, in the Indus River valley, about 6000 - 7000 years ago[42]. 
 It was transplanted into Southern India along with the Dravidian people 
who migrated to south about 2500 years ago and during this migration,   many 
plants were added into the medicine chest of Siddha treatment. 
 The Siddha System of medicine is the oldest and it is in vogue from the 
growing of vegetable kingdom on the Earth. Siddha generally refers to Ashtama 
Siddhi that is the 8th supernatural power[40]. Those who attained or achieved the 
above said powers are known as Siddhars. There were 18 important Siddhars in 
olden days and they developed this system of medicine. Hence, it is called Siddha 
Medicine. In the Indian History everyone knows that, prior to the Aryan 
migration, the Dravidians were the first inhabitants of India - of whom the South 
Indians / Tamilians were the most prominent. 
 Siddha Vaidya is also the most ancient recorded herbal medical system. 
Siddha.  It is systematic medical system, accurately defined, documented 
symptomatology and solution for reactions[43]. The well researched remedies make 
it an ideal one, as a bridge between the modern medicine and other complimentary 
medical systems. 
 Siddha Vaidya is very effective; Certain key ingredients like Amber, under 
some unique process can act instantly as effective as the modern system of 
Science. It is not true that one has to wait for days and months for a cure under 
this system. This makes this system unique and superior to other alternative 
systems. Some varieties of internal medicines, if prepared once can be used for 
hundred years. Such medicines have long life time and their potency will not be 
lost at any time, in this period. Siddha Vaidya recognizes eight branches of 
medicine, the same as western medicine except Geriatrics, the study of diseases of 
the aged. Instead Rasayana or rejuvenation therapy is given. The aim of their 
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therapy is to maintain the youth of the individual along with long life. This is 
attainable through cleanses of the body (Pancha Karma) done seasonally and 
rejuvenation treatments which activate the body's ability to rebuild and renew 
itself. According to Siddha Vaidya and Ayurveda, it is the perfect digestion and 
assimilation of our food, together with the regular and efficient evacuation of 
wastes that is essential for health and beauty. Any food, no matter how perfect, 
that is improperly digested, forms toxic wastes called 'Ama'. Ama clogs the 
system, impedes digestion, blocks vital channels and clouds the mind[43].  Siddha 
Vaidya is very effective in managing chronic diseases and degenerative conditions 
and holds many promises for the Health and Wellness of humanity. Healthy, 
functional and productive longevity is a promise from Siddha Vaidya. Another 
contribution is its wealth of knowledge regarding prophylaxis of heart diseases. 
Nano technology  
 A nanometer is one billionth of a meter, the width of six hydrogen atoms, 
or about 100,000th the size of a single grain of sand. Nano technology involves 
the manufacture and manipulation of molecules from 1-100 nanometers in size. A 
technological revolution that will irreversibly alter the way people live and work. 
It was said that by 2010, half of all drugs will be made with nano technology[40]. 
Today only we are talking about nano technology. Siddha System for centuries 
has been practicing the division of minerals into atomic weights. Atomic weight 
of hydrogen is 1.0079 atoms. Which is 1/6th the width of one nanometer. 
 It is this science and who ever practicing to this scale are the makers of 
superior medicines . For medicines to be very effective the inorganic substances 
are to be brought to their atomic form and ionic form. Today, We have on hand 
just a few of these works. Siddha system is all about not only treating illness but 
promoting youthful maintenance and rebuilding of the body. 
 Rejuvenation does not necessarily mean restoring the Old to Youth; for it 
may simply mean maintenance of youth without reaching the old age; and if youth 
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is maintained perpetually, it becomes Immortality. So Rejuvenation is a means for 
prolonging life. 
 Immortality being one of the most consoling and comforting dogma of 
religion should be reserved for aspiration of Man's faith.  It is proved that certain 
single cell creatures do not yield to natural death. Dr. Alexis Carrel, the celebrated 
biologist in his article on "tissue culture" has proved beyond doubt that it has been 
possible to keep some animal tissue almost alive and growing indefinitely in a 
suitable organic media[43]. He called them as "immortal". Cultures should, at 
frequent intervals, be transplanted to fresh media or else growth ceases and the 
cells begin to die poisoned by the accumulation of their debris and other used up 
stuffs. Similarly for the cells to be at best state, the cells of our body as well 
should be brought up in an environment, free from the contamination of the waste 
poisonous by-products in the assimilating process. 
 Therefore a high degree of constancy is to be maintained in the internal 
environment for the existence of life and health in the body, by keeping up the 
equilibrium of acid and alkaline balance in the body, eliminating the 
waste products regularly. 
Ayurveda System of Medicine 
 The word Ayurveda is made up of two words Ayu and Veda where in Ayu 
stands for life and Veda means science or knowledge. Thus Ayurveda means the 
Science of Life, Ayurveda looks not only into the physical aspect of life but it also 
goes deep into its humane aspect also. 
 It is postulated that as long as the components of soul and mind are intact, 
the biological forms of the material elements present in our body keep on 
functioning actively and keep us alive[36]. 
 Around 1500 B.C., the science of Ayurveda advanced systematically and 
was divided in eight main clinical branches.  
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9 Internal Medicine (Kaya chikitsa) 
9 Surgery, Eye, ENT (Shalya chikitsa) 
9 Obstetrics, Gynaecology, Paediatrics (Kaumar bhritya) 
9 Pharmacology (Dravya-guna) 
9 Personal care, Hygiene (Swastha-vritta) 
9 Alchemy (Rasa shastra, Bhaishajya kalpana) 
9 Prevention of diseases and improving immunity and rejuvenation 
(rasayana) 
9 Aphrodisiacs and improving health of progeny (Vajikaranam) 
As per Ayurveda, There are three basic constituents of human body: 
9 Dosha –depict the functional aspects 
9 Dhatu –depict the structural composition 
9 Mala –are end products of metabolism 
Dosha; Good health is achieved through Doshas which are considered vital 
components (catalysts) responsible for natural catabolic, anabolic and other 
physiological functions. When their levels are balanced, they maintain good 
health[38]. 
 There are of three types of Doshas  
     1.Vata –movements, catabolic process 
   Equated to nervous / endocrine system  
     2.Pitta –enzymatic functions, body heat 
   Equated to digestive system 
     3.Kapha –anabolic processes, defence mechanism  
   Equated to lymphatic system 
 
Dhatu; They are seven in number: 
  1.Rasa –Fluids of body 
  2.Rakta –Blood  
  3.Mamsa –Muscular tissue 
  4.Meda –Adipose tissue, fat 
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  5.Asthi –Bones, skeletal tissue 
  6.Majja –Bone marrow 
  7.Shukra –Semen / sperm, egg 
Malas 
 
Distinct for each Dhatu 
  Rasa –Kapha (phlegm) 
  Rakta –Pitta (bile) 
  Mamsa –Vasa (fat) 
  Meda –Sweda (perspiration) 
  Asthi-Nakha, smashru, danta 
  Majja –Akshi, nasa, snehaShukra –Smashru / oja 
 
Ayurveda in India 
 Up to 80% of people in India use either Ayurveda or other traditional 
medicines. 
 In 1970, the Indian Medical Central Council Act which aims to standardize 
qualifications for ayurveda and provide accredited institutions for its study and 
research was passed by the Parliament of India[37]. In India, over 100 colleges 
offer degrees in traditional ayurvedic medicine. The Indian government supports 
research and teaching in ayurveda through many channels at both the national and 
state levels, and helps institutionalize traditional medicine so that it can be studied 
in major towns and cities. The state-sponsored Central Council for Research in 
Ayurvedic Sciences (CCRAS) has been set up to research the subject. To fight 
biopiracy and unethical patents, the Government of India, in 2001, set up the 
Traditional Knowledge Digital Library as repository of 1200 formulations of 
various systems of Indian medicine, such as ayurveda, unani and siddha. The 
library also has 50 traditional ayurveda books digitized and available online. 
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 Central Council of Indian Medicine (CCIM) a statutory body established 
in 1971, under Department of Ayurveda, Yoga and Naturopathy, Unani, Siddha 
and Homoeopathy (AYUSH), Ministry of Health and Family Welfare, 
Government of India, monitors higher education in ayurveda. Many clinics in 
urban and rural areas are run by professionals who qualify from these institutes. 
 Ayurveda stresses the use of plant-based medicines and treatments. 
Hundreds of plant-based medicines are employed, including cardamom and 
cinnamon. Some animal products may also be used, for example milk, bones, and 
gallstones. In addition, fats are used both for consumption and for external use. 
Minerals, including sulfur, arsenic, lead, copper sulfate and gold are also 
consumed as prescribed. This practice of adding minerals to herbal medicine is 
known as rasa shastra[39]. 
 In some cases, alcohol was used as a narcotic for the patient undergoing an 
operation. The advent of Islam introduced opium as a narcotic. Both oil and tar 
were used to stop bleeding. Traumatic bleeding was said to be stopped by four 
different methods ligation of the blood vessel; cauterisation by heat; using 
different herbal or animal preparations locally which could facilitate clotting; and 
different medical preparations which could constrict the bleeding or oozing 
vessels. Various oils could be used in a number of ways, including regular 
consumption as a part of food, anointing, smearing, head massage, and prescribed 
application to infected areas. 
Herbal Treatments for Medically Challengable Disease 
 The use of herbal supplements has increased dramatically over the past 30 
years. Herbal supplements are classified as dietary supplements by the U.S. 
Dietary Supplement Health and Education Act (DSHEA) of 1994. That means 
herbal supplements -- unlike prescription drugs -- can be sold without being tested 
to prove that they are safe and effective. However, herbal supplements must be 
made according to good manufacturing practices. 
Introduction  
 
‐17‐ 
 
 The most commonly used herbal supplements in the U.S. include 
echinacea (Echinacea purpurea and related species), St. John's wort (Hypericum 
perforatum), ginkgo (Ginkgo biloba), garlic (Allium sativum), saw palmetto 
(Serenoa repens), ginseng (Panax ginseng, or Asian ginseng; and Panax 
quinquefolius, or American ginseng), goldenseal (Hydrastis canadensis), valerian 
(Valeriana officinalis), chamomile (Matricaria recutita), feverfew (Tanacetum 
parthenium), ginger (Zingiber officinale), evening primrose (Oenothera biennis), 
and milk thistle (Silybum marianum). 
 Often, herbs may be used together because the combination is more 
effective and may have fewer side effects. Health care providers must take many 
factors into account when recommending herbs, including the species and variety 
of the plant, the plant's habitat, how it was stored and processed, and whether or 
not there are contaminants (including heavy metals and pesticides). 
 Herbal medicine is used to treat many conditions, such as asthma, eczema, 
premenstrual syndrome, rheumatoid arthritis, migraine, menopausal symptoms, 
chronic fatigue, and irritable bowel syndrome, among others. Herbal supplements 
are best taken under the guidance of a trained health care provider. Be sure to 
consult with your doctor or pharmacist before taking any herbs. Some common 
herbs and their uses are discussed below. 
• Ginkgo (Ginkgo biloba) has been used in traditional medicine to treat 
circulatory disorders and enhance memory. Although not all studies agree, 
ginkgo may be especially effective in treating dementia (including 
Alzheimer's disease) and intermittent claudication (poor circulation in the 
legs). It also shows promise for enhancing memory in older adults. 
Laboratory studies have shown that ginkgo improves blood circulation by 
dilating blood vessels and reducing the stickiness of blood platelets. By the 
same token, this means ginkgo may also increase the effect of some blood-
thinning medications, including aspirin. People taking blood-thinning 
medications should ask their doctor before using ginkgo. 
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• Kava kava (Piper methysticum) is said to elevate mood, well-being, and 
contentment, and produce a feeling of relaxation. Several studies have 
found that kava may be useful in the treatment of anxiety, insomnia, and 
related nervous disorders. However, there is serious concern that kava may 
cause liver damage. It's not clear whether the kava itself caused liver 
damage in a few people or whether it was taking kava in combination with 
other drugs or herbs. It's also not clear whether kava is dangerous at 
previously recommended doses, or only at higher doses. Some countries 
have taken kava off the market. It remains available in the United States, 
but the Food and Drug Administration (FDA) issued a consumer advisory 
in March of 2002 regarding the "rare" but potential risk of liver failure 
associated with kava-containing products. 
• Saw palmetto (Serenoa repens) is used by more than 2 million men in the 
United States for the treatment of benign prostatic hyperplasia (BPH), a 
non-cancerous enlargement of the prostate gland. A number of studies 
suggest that the herb is effective for treating symptoms, including too-
frequent urination, having trouble starting or maintaining urination, and 
needing to urinate during the night. But a well-conducted study published 
in the February 9, 2006 edition of the New England Journal of Medicine 
found that saw palmetto was no better than placebo in relieving the signs 
and symptoms of BPH. 
• St. John's wort (Hypericum perforatum) is well known for its 
antidepressant effects. In general, most studies have shown that St. John's 
wort may be an effective treatment for mild to moderate depression, and 
has fewer side effects than most other prescription antidepressants. But the 
herb interacts with a wide variety of medications, including birth control 
pills, so it is important to take it only under the guidance of a health care 
provider. 
• Valerian (Valeriana officinalis) is a popular alternative to commonly 
prescribed medications for sleep problems because it is considered to be 
both safe and gentle. Some studies bear this out, although not all have 
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found valerian to be effective. Unlike many prescription sleeping pills, 
valerian may have fewer side effects such as morning drowsiness. 
• Echinacea preparations (from Echinacea purpurea and other Echinacea 
species) may improve the body's natural immunity. Echinacea is one of the 
most commonly used herbal products, but studies are mixed as to whether 
it can help prevent or treat colds. A meta-analysis of 14 clinical studies 
examining the effect of echinacea on the incidence and duration of the 
common cold found that echinacea supplements decreased the odds of 
getting a cold by 58%. It also shortened the duration of a cold by 1.4 days. 
1.1 TARGETED DRUG DELIVERY SYSTEM 
 Novel drug delivery technologies(NDDS) are revolutionizing  the drug 
delivery, development and creating R&D focused pharmaceutical industries to 
increase the momentum of global advancements. In this regard NDDS have 
benefits includes improves therapy by increase the efficacy and duration of drug 
activity, increased patient compliance through decreased dosing frequency and 
convenient routes of administration and improved site specific delivery to reduce 
unwanted adverse effects[52]. 
Targeted drug delivery, sometimes called smart drug delivery is a method of 
delivering medication to a patient in a manner that increases the concentration of 
the medication in some parts of the body relative to others[45].  
The goal of a targeted drug delivery system  
9 Drug release prolongation 
9 Localized drug effect 
9 Target and have a protected drug interaction with the diseased tissue. 
  The conventional drug delivery system is the absorption of the drug across 
a biological membrane, whereas the targeted release system is when the drug is 
released in a dosage form. 
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  Targeted drug delivery systems have been developed to optimize 
regenerative techniques. The system is based on a method that delivers a certain 
amount of a therapeutic agent for a prolonged period of time to a targeted diseased 
area within the body. This helps maintain the required plasma and tissue drug 
levels in the body[49]. Therefore, avoiding any damage to the healthy tissue via the 
drug. The drug delivery system is highly integrated and requires various 
disciplines, such as chemists, biologist and engineers, to join forces to optimize 
this system.  
A successful targeted drug delivery system comprises three elements: 
• Orientation cumulation 
• Control over drug release 
• Non-toxic and biodegradable 
Important Therapeutic Features of Tdds Include; 
1. Sufficient targeting effectiveness, circulation time, and safety (ie., lack of  
Systemic and local adverse effects) 
2. Precise subcellular localization of drugs targeted to endothelial cells 
3. adequate amplitude, kinetics, and duration of effects 
Recent research has focused on the design of phytosome and polymer 
based carrier for drug targeting. 
 Drug carrier are substances that serve as mechanisms to improve the 
delivery of drugs. Drug carriers are used in sundry drug delivery systems[44]. 
The advantages to the targeted release system  
9 Reduction in the frequency of the dosages taken by the patient 
9 More uniform effect of the drug 
9 Reduction of drug side effects 
9 Reduced fluctuation in circulating drug levels  
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 The disadvantage of the system is high cost which makes productivity 
more difficult and the reduced ability to adjust the dosages. 
Functions of Carrier Drug Delivery System 
1. Optimization of a drugs pharmacokinetics in the bloodstream and 
protection of drugs against inactivation while maintaining their biological 
and chemical properties and premature activity and route to the target[47]. 
2. Fine control of drug release kinetics 
3. Providing a template for multivalent affinity findings sites enhancing 
effectiveness of anchoring on the target cells 
4. Modulation of subcellular delivery of drugs. Nanocarriers are broadly 
defined as submicron structures that can be loaded with drugs 
  
Controllable Parameters 
  Controllable parameters of carriers that define their utility for drug 
delivery include structural materials, plasticity, morphology, size, shape, 
permeability, and biodegradability[51]. 
Carriers which are able to biodegrade include 
¾ Liposome 
¾ Phytosome 
¾ Niosome 
¾ Nanoparticle 
¾ Microspheres made of the biodegradable polymer poly(lactic co- glycolic) 
acid 
 Albumin microspheres  
 Synthetic polymers (soluble) 
 Protein DNA complex 
 
¾ Resealed Erythrocytes  
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PHYTOSOME FOR TARGETING DRUGS 
  Phytosome one of the novel colloidal drug delivery system that holds great 
promise for reaching the goal as well as site specific drug release from the 
vesicles. 
 Thus phytosome are formulated with natural phytoconstituent for 
targeting. Today, versatility of particulate technologies enables tailoring of the 
phytosome-based drug delivery system with the consideration of target, desired 
pharmacokinetic profile and route of administration[16]. 
 The important technological advantage of phytosome used as a drug 
carrier are high stability, high carrier capacity, feasibility of incorporation of 
phytoconstituent and feasibility of routes of administration. 
 These properties of phytosome enable improvement of drug bioavailability 
and reduction of the dosing frequency and may resolve the problem of non 
adherence to prescribed therapy[18]. 
Skin as a Targeting Site 
 Skin is a major target organ for allergic reactions to small molecular 
weight compounds. Drug allergic reactions may be life-threatening such as in the 
case of anaphylactic reactions or bullous drug reactions and occur in about 5% of 
all hospitalized patients. Allergic contact dermatitis has an enormous influence on 
the social life of the patient because it is the most frequent reason for occupational 
skin diseases and the treatment and prevention of this disease cost approximately 
euro 3 billion per year in Germany. The different proposed pathophysiological 
pathways leading to a drug eruption are discussed in this paper. All major 
enzymes which are involved in the metabolism of xenobiotic were shown to be 
present in skin.  
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1.2 Physiology of Skin 
   Physiological structures of skin 
 
     Figure-3  
  The human skin is the outer covering of the body. In humans, it is the 
largest organ of the integumentary system. The skin has multiple layers of 
ectodermal tissue and guards the underlying muscles, bones, ligaments and 
internal organs. Human skin is similar to that of most other mammals, except that 
it is not protected by a pelt. Though nearly all human skin is covered with hair 
follicles, it appears hairless. There are two general types of skin, hairy and 
glabrous skin. The adjective cutaneous literally means "of the skin" (from Latin 
cutis, skin). 
 Because it interfaces with the environment, skin plays a key role in 
protecting (the body) against pathogens and excessive water loss. Its other 
functions are insulation, temperature regulation, sensation, synthesis of vitamin D, 
and the protection of vitamin B folates. Severely damaged skin will try to heal by 
forming scar tissue. This is often discolored and depigmented. 
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 In humans, skin pigmentation varies among populations, and skin type can 
range from dry to oily. Such skin variety provides a rich and diverse habitat for 
bacteria which number roughly at 1000 species from 19 phyla. 
Skin is composed of three primary layers: 
• the epidermis, which provides waterproofing and serves as a barrier to 
infection; 
• the dermis, which serves as a location for the appendages of skin; and 
• the hypodermis (subcutaneous adipose layer). 
 Epidermis, "epi" coming from the Greek meaning "over" or "upon", is the 
outermost layer of the skin. It forms the waterproof, protective wrap over the 
body's surface and is made up of stratified squamous epithelium with an 
underlying basal lamina. 
 The epidermis contains no blood vessels, and cells in the deepest layers are 
nourished by diffusion from blood capillaries extending to the upper layers of the 
dermis. The main type of cells which make up the epidermis are Merkel cells, 
keratinocytes, with melanocytes and Langerhans cells also present. The epidermis 
can be further subdivided into the following strata (beginning with the outermost 
layer): corneum, lucidum (only in palms of hands and bottoms of feet), 
granulosum, spinosum, basale. Cells are formed through mitosis at the basale 
layer. The daughter cells (see cell division) move up the strata changing shape and 
composition as they die due to isolation from their blood source. The cytoplasm is 
released and the protein keratin is inserted. They eventually reach the corneum 
and slough off (desquamation). This process is called keratinization and takes 
place within about 27 days. This keratinized layer of skin is responsible for 
keeping water in the body and keeping other harmful chemicals and pathogens 
out, making skin a natural barrier to infection. 
 The epidermis contains no blood vessels, and is nourished by diffusion 
from the dermis. The main type of cells which make up the epidermis are 
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keratinocytes, melanocytes, Langerhan cells and Merkels cells. The epidermis 
helps the skin to regulate body temperature. 
 Epidermis is divided into several layers where cells are formed through 
mitosis at the innermost layers. They move up the strata changing shape and 
composition as they differentiate and become filled with keratin. They eventually 
reach the top layer called stratum corneum and are sloughed off, or desquamated. 
This process is called keratinization and takes place within weeks. The outermost 
layer of the epidermis consists of 25 to 30 layers of dead cells. 
Epidermis is divided into the following 5 sublayers or strata: 
9 Stratum corneum 
9 Stratum lucidum 
9 Stratum granulosum 
9 Stratum spinosum 
9 Stratum germinativum  
Dermis 
 The dermis is the layer of skin beneath the epidermis that consists of 
connective tissue and cushions the body from stress and strain. The dermis is 
tightly connected to the epidermis by a basement membrane. It also harbors many 
Mechanoreceptor/nerve endings that provide the sense of touch and heat. It 
contains the hair follicles, sweat glands, sebaceous glands, apocrin glands, 
lymphatic vessels and blood vessels. The blood vessels in the dermis provide 
nourishment and waste removal from its own cells as well as from the Stratum 
basale of the epidermis. 
 The dermis is structurally divided into two areas: a superficial area 
adjacent to the epidermis, called the papillary region, and a deep thicker area 
known as the reticular region. 
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Papillary region 
 The papillary region is composed of loose areolar connective tissue. It is 
named for its fingerlike projections called papillae, that extend toward the 
epidermis. The papillae provide the dermis with a "bumpy" surface that 
interdigitates with the epidermis, strengthening the connection between the two 
layers of skin. 
 In the palms, fingers, soles, and toes, the influence of the papillae 
projecting into the epidermis forms contours in the skin's surface. These are called 
friction ridges, because they help the hand or foot to grasp by increasing friction. 
Friction ridges occur in patterns that are genetically and epigenetically determined 
and are therefore unique to the individual, making it possible to use fingerprints or 
footprints as a means of identification. 
Reticular region 
 The reticular region lies deep in the papillary region and is usually much 
thicker. It is composed of dense irregular connective tissue, and receives its name 
from the dense concentration of collagenous, elastic, and reticular fibers that 
weave throughout it. These protein fibers give the dermis its properties of 
strength, extensibility, and elasticity. 
 Also located within the reticular region are the roots of the hair, sebaceous 
glands, swea glands, receptors, nails, and blood vessels. 
 Tattoo ink is held in the dermis. Stretch marks from pregnancy are also 
located in the dermis. 
Hypodermis 
 The hypodermis is not part of the skin, and lies below the dermis. Its 
purpose is to attach the skin to underlying bone and muscle as well as supplying it 
with blood vessels and nerves. It consists of loose connective tissue and elastin. 
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The main cell types are fibroblasts, macrophages and adiposities (the hypodermis 
contains 50% of body fat). Fat serves as padding and insulation for the body. 
 Microorganisms like Staphylococcus epidermidis colonize the skin 
surface. The density of skin flora depends on region of the skin. The disinfected 
skin surface gets recolonized from bacteria residing in the deeper areas of the hair 
follicle, gut and urogenital openings. 
Drug Transport Across Skin 
 The stratum corneum is the outermost desquamating ‘horny’ layer of skin, 
comprising about 15-20 rows of flat, partially desiccated, dead, keratinized 
epidermal cells. Depending upon the region of the body, the thickness of this layer 
ranges from 10-20 µm, with the thickest layer on the palms of the hands and soles 
of the feet. Of the various skin layers, it is the stratum corneum that is the rate-
limiting barrier to percutaneous drug transport. In fact, the stratum corneum is a 
remarkably more formidable barrier to drug transport than the epithelial barriers 
of gastrointestinal, nasal, buccal, vaginal, or rectal delivery routes.  
 
 Transport of hydrophilic or charged molecules is especially difficult 
attributable to the lipid-rich nature of the stratum corneum and its low water 
content; this layer is composed of about 40% lipids, 40% protein, and only 20% 
water. Transport of lipophilic drug molecules is facilitated by their dissolution into 
intercellular lipids around the cells of the stratum corneum. Absorption of 
hydrophilic molecules into skin can occur through ‘pores’ or openings of the hair 
follicles and sebaceous glands, but the relative surface area of these openings is 
barely 1% of the total skin surface. This small surface area limits the amount of 
drug absorption.  
 
 Percutaneous absorption of drug molecules is of particular importance in 
the case of transdermal drug delivery systems because the drug has to be absorbed 
to an adequate extent and rate to achieve and maintain uniform, systemic, 
Introduction  
 
‐28‐ 
 
therapeutic levels throughout the duration of use. In general, once drug molecules 
cross the stratum corneal barrier, passage into deeper dermal layers and systemic 
uptake occurs relatively quickly and easily.  
 
 Generally, drug absorption into the skin occurs by passive diffusion. The 
rate of drug transport across the stratum corneum follows Fick’s Law of Diffusion 
(see box below). In other words, the rate of drug transport depends not only on its 
aqueous solubility, but is also directly proportional to its oil/water partition 
coefficient, its concentration in the formulation vehicle, and the surface area of the 
skin to which it is exposed; it is inversely proportional to the thickness of the 
stratum corneum. The stratum corneum is thickest in the plantar (soles) and 
palmar regions and thinnest in the postauricular, axillary, and scalp regions of the 
body. An understanding of the transport behavior of drugs is vital for designing an 
effective topical or transdermal product, as well as reasonably predicting and 
comparing drug behavior in various formulations. The latter is of practical 
importance to the pharmacist who is required to suggest one or more effective 
drug products out of the many commercial formulations available or to counsel 
patients on proper use and handling of topical and transdermal products.  
  
Fick’s Law of Diffusion as applied to drug transport across stratum corneum 
   
  dM    D∆CK  
   dt  h  
 where, 
 dM/dt  =   is the steady-state flux across stratum corneum  
   D       =       is the diffusion coefficient or diffusivity of drug molecules  
 ∆C       =      is the drug concentration gradient across the stratum  
corneum  
  K        =      is the partition coefficient of the drug between skin  
        and formulation medium, and 
   h        =     is the thickness of the stratum corneum 
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1.3 PHYTOSOME - A REVIEW 
 
 Over the past century, scientific technology has established the 
compositions, biological activities, and health-promoting benefits of numerous 
botanical products. Water-soluble phytoconstituents like flavonoids, tannins, 
terpenoids, etc. are poorly absorbed either due to their large molecular size, which 
cannot be absorbed by passive diffusion, or due to their poor lipid solubility, 
severely limiting their ability to pass across the lipid-rich (outer membranes of the 
enterocytes of the small intestine) biological membranes, resulting in poor 
bioavailability.   
 
 An ideal drug delivery system is the one that delivers the drug at a rate 
dictated by the need of the body, over the period of treatment, and channels the 
active entity solely to the site of action. For this purpose, a number of carriers 
have been used, like immunoglobins, erythrocytes, reverse micelles, phytosomes, 
pharmacosomes, etc. Phytosomes have improved pharmacokinetic and 
pharmacological parameters that result in the treatment of acute and chronic liver 
disease of toxic metabolic or infective origin or of a degenerative nature. These 
are also widely used in anti-inflammatory activity and pharmaceutical and 
cosmetic compositions. 
 
 Phytosomes are novel drug delivery system containing hydrophilic 
bioactive phytoconstituents of herbs surround and bound by phospholipids. 
    
Structure of Phytosome 
 
 
     
 
 
 
 
 
Figure-4 
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 Development of phytosomes is at the budding stages in India and abroad. 
It has a lot of potential in the field of medicine, pharmaceuticals and cosmetics.  
 
 The technology has improved pharmacokinetics and pharmacological 
parameters.  
 
 It is found to be safe and efficacious, which in result can advantageously 
be used in the treatment of various diseases of human beings and animals.  
 
  These drug-phospholipid complexes can be formulated in the form of 
solution, suspension, emulsion, syrup, lotion, gel, cream, aqueous 
microdispersion, pill, capsule, powder, granules and chewable tablet 
 
 For good bioavailability, natural products must have a good balance 
between hydrophilicity (for dissolving into the gastro-intestinal fluids) and 
lipophilicity (to cross lipidic biomembranes). 
 
  Many phytoconstituents like polyphenolics have good water solubility, 
but are, nevertheless poorly absorbed  because of their large size, incompatible 
with a process of passive diffusion and/or their poor miscibility with oils and other 
lipids. 
  
 As a result, the ability of flavonoids to cross the lipid-rich outer membrane 
of small intestine enterocytes is severely limited.  
 
 Water-soluble phytoconstituents (mainly polyphenolics) can be converted 
into a lipid-compatible molecular complex known as Phytosomes.  
 
 A Phytosome is generally more bioavailable than  simple herbal extract 
due to its enhanced capacity to cross the lipid-rich biomembranes and reach 
circulation.  
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 Phospholipids are small lipid molecules where glycerol is bonded to two 
fatty acids, while the third hydroxyl, normally one of the two primary methylenes, 
bears a phosphate group bound to a biogenic amino or to an amino acid thus 
making Phytosomes different from liposomes.  
 
 Phospholipids from soy, mainly phosphatidylcholine, are lipophilic agents, 
and readily complex polyphenolics. In this context, phosphatidylcholine, the 
major molecular building block of cell membranes and a compound miscible in 
both water and in oil/lipid environments, is well absorbed orally, and has the 
potential to act as a chaperon for polyphenolics, shuttling them through biological 
membranes 
 
Preparation of Phytosome 
 
 Phytosomes are prepared by reacting from 3-2 moles but preferably with 
one mole of natural or synthetic phospholipids, with one mole of component like 
flavolignans, either alone or in the natural mixture in aprotic solvent such as 
dioxane or acetone.  
 
 The phytosome complex can be then isolated by precipitation with non 
solvent such as aliphatic hydrocarbons or lyophilization or by spray drying. In the 
complex formation of phytosomes the ratio between these two moieties is in the 
range from 0.5- 2.0 moles. After the organic solvent was removed under vacuum 
condition, phospholipid complex was formed.  
 
 
 In the phytosome preparations, phospholipids are selected from the group 
consisting of soy lecithin, from bovine or swine brain or dermis, 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine in which acyl 
group may be same or different and mostly derived from palmitic, stearic, oleic 
and linoleic acid.  
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 Selection of flavonoids are done from the group consisting of quercetin, 
kaempferol, quercretin-3, rhamnoglucoside, quercetin-3-rhamnoside, hyperoside, 
vitexine, diosmine, 3- rhamnoside, (+) catechin, (-) epicatechin, apigenin-7-
glucoside, luteolin, luteolinglucoside, ginkgonetine, isoginkgonetine and 
bilobetine. [20] Phytosomes are different than liposomes in the way it incorporates 
the water soluble drug to form the complex.  
 
 A liposome is formed by mixing a water soluble substance with 
phosphatidylcholine in definite ratio under specific conditions. Here, no chemical 
bond is formed; the phosphatidylcholine molecules surround the water soluble 
substance.  
 
 In contrast, the phytosome process the phosphatidylcholine and the plant 
components actually form a 1:1 or a 2:1 molecular complex depending on the 
substance(s) complexed, involving chemical bonds. 
 
  Fundamental differences are that in liposomes, the active principles are 
dissolved in the central part of the cavity, with no possibility of molecular 
interaction between the surrounding lipid and a hydrophilic substance.  On the 
other hand the phytosome complex can somewhat be compared to an integral part 
of the lipid membrane, where the polar functionalities of the lipophilic guest 
interact via hydrogen bonds with the polar head of a phospholipids (i.e. phosphate 
and ammonium groups), forming a unique pattern which can be characterized by 
Spectroscopy.   
 
 This difference results in phytosome being much better absorbed than 
liposomes showing better bioavailability.  
 
 Phytosomes are also superior to liposomes in skin care products while the 
liposome is an aggregate of many phospholipids molecules that can enclose other 
phyto active molecules but without specifically bonding to them. Liposomes are 
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touted delivery vehicles, but for dietary supplements their promise has not been 
fulfilled.  
 
 But for phytosome products numerous studies prove they are markedly 
better absorbed and have substantially greater clinical efficacy. Companies have 
successfully applied this technology to a number of standardized flavonoids 
preparations. 
 
 Some liposomal drugs complex operate in the presence of the water or 
buffer solution where as phytosomes operate with the solvent having a reduced 
dielectric constant. Starting material of component like flavonoids is insoluble in 
chloroform, ethyl ether or benzene. They become extremely soluble in these 
solvents after forming phytosomes. This chemical and physical property change is 
due to the formation of a true stable complex. 
   
  Difference between Phytosome and Liposome 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure-5 
 
Introduction  
 
‐34‐ 
 
Characterization of Phytosome 
 
 The behavior of phytosomes in both physical and biological system is 
governed by the factors such as physical size, membrane permeability; percentage 
entrapped solutes, chemical composition, quantity and purity of the starting 
materials. 
 
 Therefore, the phytosomes are characterized for physical attributes like 
shape, size, distribution, percentage drug capture entrapped volume, percentage 
drug released and chemical composition.  
  
 Complexation and molecular interactions between phytoconstituents and 
phosphatidylcholine in solution have been studied by 1H-NMR ,13C-NMR, 
31PNMR, [26] as well as by IR spectroscopy .  
 
 Thermal gravimetric analysis (TGA) and differential scanning calorimetry 
(DSC) are other techniques employed for the detection and measurement of 
thermal effects such as fusion, solid–solid transitions, glass transitions, loss of 
solvent, and decomposition to characterize a solid phytosome.  
 
 
 Further NMR data available on the marketed phytosomes also indicates 
that the signals of the fatty chain are almost unchanged. Such evidences inferred 
that the two long aliphatic chains are wrapped around the active principle, 
producing a lipophilic envelope, which envelope the polar head of the 
phospholipids and the herbal extract. 
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Physical and Chemical Properties of Phytosomes 
 
 They are lipophilic substances with a definite melting point, freely soluble 
in non polar and aprotic solvents in which the hydrophilic moiety is not.  
 
 They are moderately soluble in fats and insoluble in water. When treated 
with water, they assume a micelle shape, forming structures which resemble 
liposome. 
 
  In these complexes, the polar head of the phospholipid is involved while 
the fatty acid moieties retain a high degree of mobility conferring marked 
lipophilia at the new molecule.  
 
 In the 1H-NMR spectrum, the signals of the complexed substances 
undergo a strong broadening so as they can no more be evidenced in the spectra.  
 
 
 In the 13C-NMR spectrum, the signals of the complexed substances as 
well as those of the choline and glycerin portion of the phospholipid can no more 
be recorded . 
 
 The phosphorous nucleus itself undergoes a band broadening which 
indicates that it is involed in complex formation. In both the 1H-NMR and 13C-
NMR spectra, only the lipid chain signals appear, even showing some 
immobilization.  
 
 The kind of signals proves the interaction between polar head and active 
sites of the complex whereas the lipid chains are not involved since they are free 
to rotate and give complex its lipophilic character. 
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Advantages of Phytosome  
 
Phytosomes have the following advantages 
  
1) Phytosome are better bioavailable botanical extracts, dramatically enhance 
bioavailability due to their complex with phospholipids and delivers faster 
and improved absorption in intestinal tract. 
 
2) They enhance the absorption of lipid insoluble polar phytoconstituents 
through oral as well as topical route showing better bioavailability with 
significantly better therapeutic benefit. 
 
3) Dose requirement can be minimized as the bioavailability is increased. 
 
4) Phosphatidylcholine used in preparation of phytosomes besides acting as a 
carrier also acts as a hepatoprotective substance showing the synergistic 
effect when hepatoprotective substances like flavanoids are employed to 
form complex. 
 
5) Phytosome are widely used in cosmetics due to there more skin 
penetration and high lipid profile. 
 
6) Phytosomes show better stability profile owing to the chemical bonds 
formed between phosphatidylcholine molecule and phytoconstituents. 
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1.4 WART OVERVIEW 
 
 A wart is generally a small, rough growth, typically on a human’s hands 
or feet but often other locations, that can resemble a cauliflower or a solid blister.  
 
 They are caused by a viral infection, specifically by one of the many types 
of human papillomavirus. There are as many as 10 varieties of warts, the most 
common considered to be mostly harmless. It is possible to get warts from others; 
they are contagious and usually enter the body in an area of broken skin. They 
typically disappear after a few months but can last for years and can recur. 
 
Types 
 
A range of types of wart have been identified, varying in shape and site 
affected, as well as the type of human papillomavirus involved. These include: 
• Common wart (Verruca vulgaris), a raised wart with roughened surface, 
most common on hands, but can grow anywhere on the body; 
• Flat wart (Verruca plana), a small, smooth flattened wart, flesh-coloured, 
which can occur in large numbers; most common on the face, neck, hands, 
wrists and knees; 
• Filiform or digitate wart, a thread- or finger-like wart, most common on 
the face, especially near the eyelids and lips; 
• Genital wart (venereal wart, Condyloma acuminatum, Verruca acuminata), 
a wart that occurs on the genitalia. 
• Mosaic wart, a group of tightly clustered plantar-type warts, commonly on 
the hands or soles of the feet; 
• Periungual wart, a cauliflower-like cluster of warts that occurs around the 
nails. 
• Plantar wart (verruca, Verruca plantaris), a hard sometimes painful lump, 
often with multiple black specks in the center; usually only found on 
pressure points on the soles of the feet; 
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CAUSES 
 Warts are caused by the Human papilloma virus (HPV). There are about 
130 known types of human papilloma viruses. HPV infects the squamous 
epithelium, usually of the skin or genitals, but each HPV type is typically only 
able to infect a few specific areas on the body. Many HPV types can produce a 
benign growth, often called a "wart" or "papilloma", in the area they infect. Many 
of the more common HPV and wart types are as follows: 
• Common warts - HPV types 2 and 4 (most common); also types 1, 3, 26, 
29, and 57 and others  
• Cancers and Genital dysplasia - "high-risk" HPV types are associated with 
cancers, (cervical cancer and can also cause some vulvar, vaginal, penile, 
anal and some oropharyngeal cancers. "low-risk" types are associated with 
warts or other conditions)  
• High-risk: 16, 18 (cause the most cervical cancer); also 58, 33, 45, 31, 52, 
35, 39, 59, and others  
• Plantar warts (myrmecia) - HPV type 1 (most common); also types 2, 3, 4, 
27, 28, and 58 and others  
• Anogenital warts (condylomata acuminata or venereal warts) - HPV types 
6 and 11 (most common); also types 42, 44 and others  
• Low-risk: 6, 11 (most common); also 13, 44, 40, 43, 42, 54, 61, 72, 81, 89, 
and others  
• Flat warts - HPV types 3, 10, and 28 
• Butcher's warts - HPV type 7 
• Heck's disease (Focal epithelial hyperplasia) - HPV types 13 and 32. 
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Pathophysiology 
 Common warts have a characteristic appearance under the microscope. 
They have thickening of the stratum corneum (hyperkeratosis), thickening of the 
stratum spinosum (acanthosis), thickening of the stratum granulosum, rete ridge 
elongation, and large blood vessels at the dermoepidermal junction. 
Prevention 
 Gardasil is a HPV vaccine aimed at preventing cervical cancers and genital 
warts. Gardasil is designed to prevent infection with HPV types 16, 18, 6, and 11. 
HPV types 16 and 18 currently cause about 70% of cervical cancer cases and also 
cause some vulvar, vaginal, penile and anal cancers. HPV types 6 and 11 are 
responsible for 90% of documented cases of genital warts. Unfortunately the HPV 
vaccines do not currently prevent the virus strain responsible for verrucas (plantar 
warts) 
Treatment 
 There are many treatments and procedures associated with wart removal. 
One review of 52 clinical trials of various cutaneous wart treatments concluded 
that topical treatments containing salicylic acid were the best supported, with an 
average cure rate of 75%, compared with 48% for the placebo in six placebo-
controlled trials including a total of 376 participants. The reviewers also 
concluded that there was little evidence of a significant benefit of cryotherapy 
over salicylic acid or duct tape. 
 
 One complicating factor in the treatment of warts is that the wart may 
regrow after it has been removed. 
 
Treatments that may be prescribed by a medical professional include 
 
• Application of podophyllum resin paint [podophyllum resin I.P.'66 (20% 
w/v), benzoin I.P. (10% w/v), aloes I.P. (2% w/v), isopropyl alcohol I.P. to 
make (100% v/v)] 
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• Imiquimod, a topical cream that helps the body's immune system fight the 
wart virus by encouraging interferon production. Approved by the U.S. 
Food and Drug Administration (FDA) for genital warts. The drug is very 
expensive 
• Cantharidin, a chemical found naturally in many members of the beetle 
family Meloidae which causes dermal blistering. Either used by itself or 
compounded with podophyllin Not FDA approved, but available through 
Canada or select US compounding pharmacies. 
• Bleomycin, not USFDA approved. One or two injections used. It can cause 
necrosis of digits and Raynaud syndrome 
• Dinitrochlorobenzene (DNCB), like salicylic acid, this is applied directly 
to the wart. Studies showed this method was effective with a cure rate of 
80%. But DNCB must be used much more cautiously than salicylic acid; 
the chemical is a known mutagen, able to cause genetic mutations. So a 
physician must administer DNCB. This drug induces an allergic immune 
response resulting in inflammation that wards off the wart-causing virus 
 
• Fluorouracil, which inhibits DNA synthesis, is being used as an 
experimental treatment. It is applied directly to the wart (especially plantar 
warts) and covered (for example: with tape). This treatment is combined 
with the use of a pumice stone, but tends to work very slowly 
• Salicylic acid can be prescribed by a dermatologist in a higher 
concentration than that found in over-the-counter products. Examples 
include a topical solution marketed by Elorac, Inc. under the trade name 
Durasal 
 There are several over-the-counter options. The most common ones 
involve salicylic acid. These products are readily available at drug stores and 
supermarkets. There are typically two types of products: adhesive pads treated 
with salicylic acid or a bottle of concentrated salicylic acid solution. Removing a 
wart with salicylic acid can be done by cleaning the area, applying the acid, and 
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removing the dead skin with a pumice stone or emery board. It may take up to a 
year to remove a wart. 
 Another product available over-the-counter that can aid in wart removal is 
silver nitrate in the form of a caustic pencil, which is also available at drug stores. 
In a placebo-controlled study of 70 patients, silver nitrate given over nine days 
resulted in clearance of all warts in 43% and improvement in warts in 26% one 
month after treatment compared to 11% and 14%, respectively, in the placebo 
group. The instructions must be followed to minimize staining of skin and 
clothing. Occasionally pigmented scars may develop. 
 Cryosurgery or cryotherapy devices using a dimethyl ether - propane 
mixture are inexpensive. A disadvantage is that the sponge applicator is too large 
for small warts, and the temperature achieved is not nearly as low as with liquid 
nitrogen. Complications include blistering of normal skin if excess freezing is not 
controlled. 
 Several randomized, controlled trials have found that zinc sulfate, 
consumed orally, often reduces or eliminates warts. The zinc sulfate dosage used 
in medical trials for treatment of warts was between 5 and 10 mg/kg/day. For 
elemental zinc, a lower dosage of 2.5 mg/kg/day may be appropriate as large 
amounts of zinc may cause a copper deficiency. Other trials have found that 
topical zinc sulfate solution or zinc oxide are also effective. 
Procedures 
 
• Keratolysis, of dead surface skin cells usually using salicylic acid, 
blistering agents, immune system modifiers ("immunomodulators") or 
formaldehyde, often with mechanical paring of the wart with a pumice 
stone, blade etc., 
• Electrodesiccation 
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• Cryosurgery, which involves freezing the wart (generally with liquid 
nitrogen), creating a blister between the wart and epidermal layer, after 
which the wart and surrounding dead skin falls off by itself. An average of 
3 to 4 treatments are required for warts of thin skin. Warts on calloused 
skin like plantar warts might take dozens or more treatments. 
• Surgical curettage of the wart 
• Laser treatment - often with a pulse dye laser or carbon dioxide (CO2) 
laser. Pulse dye lasers (wavelength 582 nm) work by selective absorption 
by blood cells (specifically haemoglobin). CO2 lasers work by selective 
absorption by water molecules. Pulse dye lasers are less destructive and 
more likely to heal without scarring. CO2 laser works by vaporizing and 
destroying tissue and skin. Laser treatments can be painful, expensive 
(though covered by many insurances) and can cause little scarring when 
used appropriately. CO2 lasers will require local anaesthetic. Pulse dye 
laser treatment does not need conscious sedation nor local anesthetic. It 
takes 2 to 4 treatments but can be many more for extreme cases. Typically, 
10-14 days are required between treatments. Preventative measures are 
important 
• Infrared coagulator - an intense source of infrared light in a small beam 
like a laser. This works essentially on the same principle as laser treatment. 
It is less expensive. Like the laser, it can cause blistering pain and scarring 
• Duct tape occlusion therapy involves placing a piece of duct tape over the 
wart. The evidence as to whether or not it is effective is poor. Thus it is not 
recommended as routine treatment. 
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Folk Remedies 
 A variety of traditional folk remedies and rituals claim to be able to 
remove warts. In The Adventures of Tom Sawyer, Mark Twain has his characters 
discuss a variety of such remedies. Tom Sawyer proposes "spunk-water" (or 
"stump-water", the water collecting in the hollow of a tree stump) as a remedy for 
warts on the hand.  
 One remedy for warts involves rubbing the wart with a potato, which is 
then buried; when the "buried potato dries up, the wart will be cured" 
  Another remedy similar to Twain's is reported from Northern Ireland, 
where water from a specific well on Rathlin Island is credited with the power to 
cure warts 
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CHAPTER - 2 
LITERATURE REVIEW OF THUJA OCCIDENTALIS 
 
Kim JY et.al., 2011, Thuja occidentalis (TO) has been a recognized herbal 
medicine across Northeast Asian countries for thousands of years and used for the 
treatment of various inflammatory diseases through as yet undefined mechanisms. 
In this study, he concluded that that the anti-inflammatory effects of this plant are 
mediated to suppress mitogen-activated protein kinases (MAPKs) and nuclear 
factor-κB (NF-κB) activation in lipopolysaccharide (LPS)-stimulated RAW 264.7 
cells. 
Huaping et.al., 2010, The essential oils from leaves, twigs and stems of large 
trees and shrub-like trees of Thuja sutchuenensis were extracted by 
hydrodistillation and supercritical fluid extraction, and analyzed by GC and GC-
MS. The essential oil composition differed significantly among the three organs, 
as well as between large trees and shrub-like trees. Furthermore, consistent with 
the eastern Asia-North American disjunct distribution of the genus, many 
differences in the essential oil composition between T. sutchuenensis and other 
Thuja species were apparent. The essential oils exhibited a certain degree of 
antifungal activity against six strains of human pathogenic fungi. 
Lee YJ et.al., 2010, Studied in vitro screening of 600 medicinal plant extracts, an 
aqueous extract of Thuja occidentalis (ATO) was found to exhibit 
antiinflammatory activity in human umbilical vein endothelial cells (HUVEC). In 
the current study, the anti inflammatory activity of ATO and possible mechanisms 
for this were investigated in HUVEC. Pre incubation with ATO (20µg/ml) 
suppressed tumor necrosis factor-α (TNF-α)-induced expression of adhesion 
molecules including intercellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule-1 (VCAM-1) and E-selectin at both the protein and mRNA 
levels. ATO also inhibited U937 monocyte adhesion to HUVEC stimulated by 
TNF-α. In addition, ATO attenuated TNF-α-induced p65 NF-κB translocation into 
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the nucleus and phosphorylation of IκB-α. Furthermore, ATO significantly 
inhibited TNF-α-induced intracellular reactive oxygen species (ROS) production. 
Overall, the present data suggest that ATO can suppress TNF-α-induced vascular 
inflammatory processes, possibly via inhibition of ROS and NF-κB activation in 
HUVEC. 
B.K.Ojeswi et.al., 2010, In vivo experiment has been conducted to observe the 
preventive role of Thuja occidentalis Linn (leaves) against 7, 12 
dimethylbenz(a)anthracene (DMBA)-induced mammary cancer. Ethyl acetate 
(EtOAc) and methanolic (MeOH) extracts in two doses (5 and 10 mg/kg body 
weight) of the plant were tested for DMBA-induced Indian Cancer Research 
Centre (ICRC) mice mammary carcinoma in terms of tumor weight, volume, life 
span, histological variation and oxidative stress against the reference drug 
doxorubicin using standard animal protocol. EtOAc extract (10 mg/kg body 
weight) of the plant exhibits reduction of tumor weight (39%), tumor volume 
(50%), reduced glutathione (GSH) (83%) and malignant cells compared to 
cancerous control group while the increase in body weight and life span in 
comparison with cancerous control and doxorubicin-treated group. EtOAc extract 
being most potent extract has been subjected to detailed chromatographic 
separation. The most potent chromatographic fraction exhibits the presence of 
flavonoidal unit. Structural elucidation of bioactive principle is in progress. It is 
inferred that the plant T. occidentalis (leaves) possess significant potential for 
phytopreventive bioefficacy against DMBA-induced mammary carcinogenesis 
Dimitroula Tsiri et.al., 2009,  identified essential oils of four varieties of Thuja 
species cultivated in Poland - T. occidentalis, T. occidentalis, T. plicata - were 
investigated by GC and GC-MS. Thirty-one compounds were identified from T. 
occidentalis 'globosa', representing 96.92% of the total oil; twenty-seven from T. 
occidentalis 'aurea' (94.34%); thirty-one from T.plicata (94.75%); and thirty 
compounds from T. plicata 'gracialis' (96.36%). The main constituents in all 
samples were the monoterpene ketones alpha- and beta-thujone, fenchone and 
sabinene, as well as the diterpenes beyerene and rimuene. The chemosystematic 
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value of the total ketone content of all samples (which varied from 54.30-69.18%) 
has been discussed and investigated. The constituents, beyerene and the mixture 
of alpha- and beta-thujone, were isolated from the oils and tested against six 
Gram-positive and -negative bacteria and three pathogenic fungi. The oils of the 
two T. plicata species exhibited significant antimicrobial activity, while the 
mixture of alpha- and beta-thujone showed very strong activity as well. 
Choo SJ et.al., 2009, Demonstrated free radical scavenging and antielastase 
activity of Flavanoids from the extract of Thuja occidentalis. And he concluded 
that The free radical scavenging and human neutrophil elastase (HNE) inhibitory 
activities were evaluated for the isolated compounds  by using DPPH (2,2-
diphenyl-1-picrylhydrazyl) assay. 
Sunila ES et.al., 2006, Demonstrated Thuja occidentalis extract on the inhibition 
of lung metastasis induced by B16F-10 melanoma cells was studied in C57BL/6 
mice. The extract was administered by three different modalities. A remarkable 
reduction in tumor-nodule formation was shown by simultaneous (74.4%) and 
prophylactic (71.5%) mode of administration. The effect was comparatively low 
in drug administration after tumor development (60.2%). Increased lung collagen 
hydroxyproline (21.13 microg/mg protein) in the metastasized lungs of control 
animals compared with normal animals (0.98 microg/mg protein) was 
significantly reduced in Thuja-treated animals 
Sunila ES et.al., 2005, was carried the research on Thuja occidentalis against 
damage induced by gamma radiation in mice. Whole-body exposure of Swiss 
albino mice to gamma-rays (6 Gy) reduced the total white blood cell count to 
1900 cells/mm(3) on the third day, which was elevated to 2050 cells/mm(3) by the 
administration of alcoholic extract of T.occidentalis (5 mg/dose/animal, 
intraperitoneally). Six animals from each group were killed after 2, 7, and 11 days 
of irradiation to detect the bone marrow cellularity and radiation-induced toxicity. 
The number of bone marrow cells and alpha-esterase positive cells in control 
animals after 11 days was reduced to 12.2 x 10(6) cells/femur and 693.5/4000 
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cells, respectively. In T occidentalis-treated animals, bone marrow cellularity was 
increased to 16.9 x 10(6) cells/femur and alpha-esterase positive cells were 
940/4000 cells, a nearly normal level. Alcoholic extract of T.occidentalis reduced 
the elevated levels of GPT and alkaline phosphatase in liver and serum after 
irradiation. 
Girish gupta et.al., 2002, Antimycotic Potential of Thuja occidentalis against 
Curvularia-lunata causing Phaeoyphomycosis was studied. In Human, Various 
potencies of a homoeopathic drug, Thuja-occidentalis-Q 30, 200, 1M, 10M and 
50M and Ketoconazole (a synthetic dioxolane imidazole compound-a broad 
spectrum antifungal) as a positive control were evaluated by following Poison 
food method. Finally he concluded that, Thuja 30 and 200 was found highly 
effective even more than positive control and vehicle. 
Offergeld R et.al.,1998,Studied the antiviral & immune stimulatory activity of 
Thuja occidentalis was shown to be an inducer of the CD4+ fraction of the human 
peripheral blood T-cell subset (1,2). Furthermore, it could be demonstrated that 
TPSg is a potent inhibitor of the expression of HIV-1-specific antigens and of the 
HIV-1-specific reverse transcriptase (3). This report deals with the cytokine 
pattern induced by TPSg in human peripheral blood lymphocyte (PBL) and 
purified monocyte/macrophage cultures. In addition, a further characterization of 
the CD4+ T-cell fraction stimulated by TPSg was performed by FACS analysis. 
TPSg is induces IL-1 beta, IL-2, IL-3, IL-6, gamma-IFN, G-CSF, GM-CSF, and 
TNF-beta production in PBL cultures; and IL-1 beta and IL-6 in 
monocyte/macrophage cultures. Enzyme-linked immunosorbent assays (ELISAs) 
demonstrated that no IL-4 was produced by PBL cultures under TPSg influence. 
Belal naser et.al., 1995, Demonstrated antiviral and immunopharmacological 
potential, such as stimulatory and co-stimulatory effects on cytokine and antibody 
production and activation of macrophages and other immunocompetent cells. And 
he concluded thuja occidentalis having effective antiviral and immunostimulatory 
effects. 
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2.1  LITERATURE REVIEW OF WART 
A Shakoor et.al., 2012, Demonstrated the Effects of Thuja Occidentalis as an 
alternative remedy in the treatment of Papillomatosis in Cattle. Papillomatosis is a 
condition in farm animals and is treated by surgical excision or application of 
certain caustic agents. Contrary to it, two cattle with teat warts were treated by an 
alternative method by using the Thuja occidentalis (thuja-30, a homeopathic 
medicine) 10 drops twice a day for a span of 3 weeks and lead to complete 
recovery. 
 
Anca Gaston et.al, 2012,  Salicylic acid and cryotherapy are the most frequent 
treatments for common warts, but can be painful and cause scarring, and have 
high failure and recrudescence rates. Topical vitamin A has been shown to be a 
successful treatment of common warts. He demonstrated with healthy, 
physically-active 30 old female with a 9 year history of common warts on the 
back of the right hand. The warts resisted treatment with salicylic acid, apple 
cider vinegar and an over-the-counter blend of essential oils marketed for the 
treatment of warts. Daily topical application of natural vitamin A derived from 
fish liver oil (25,000 IU) led to replacement of all the warts with normal skin. 
Most of the smaller warts had been replaced by 70 days. A large wart on the 
middle knuckle required 6 months of vitamin A treatment to resolve completely. 
 
Yu-guo Pu et.al., 2009, Interferon has been widely used in the treatment of 
genital warts for its immunomodulatory, antiproliferative and antiviral properties. 
Currently, no evidence that interferon improves the complete response rate or 
reduces the recurrence rate of genital warts has been generally provided. He 
demonstrated with involving 1445 people were included. Among them, 7 studies 
demonstrated the complete response rate of locally-used interferon as compared to 
placebo for treating genital warts. Based on meta-analysis, the rate of Complete 
response of the two interventions differed significantly (locally-used 
interferon:44.4%; placebo:16.1%).and finally he concluded that,Interferon tends 
to be a fairly well-tolerated form of therapy. According to different routes of 
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administration, locally-used interferon appears to be much more effective than 
both systemically-used interferon and placebo in either improving the complete 
response rate or reducing the recurrence rate for the treatment of genital warts. 
 
Allice Rosenberg et.al., 2008, Carried the research on genital wart by treating 
them with cryotherapy. And he demonstrated that the Untreated anogenital warts 
can spread and form large clusters that are bothersome, painful, and embarrassing 
to the patient as well as being a significant health risk. Approximately 10% of 
HIV positive patients have anogenital warts. He concluded that, the anogenital 
warts are successfully treated with cryotherapy. 
U.R. Hengge et,al., 2008, Imiquimod, a novel topical immune response modifier, 
has been successfully used for the treatment of external anogenital warts. 
Demonstrated  the safety, tolerance and efficacy of imiquimod for the treatment of 
common cutaneous warts and mollusca that were resistant to previous therapeutic 
interventions. Imiquimod 5% cream was self-applied by the patients to the warts 
or mollusca once daily for 5 days per week and left in place overnight. Patient-
applied 5% imiquimod cream holds promise as an effective treatment of common 
warts and mollusca in a difficult-to-treat patient population. 
Rachel Wenner. MD  et.al., 2007, Evaluated the efficacy of duct tape occlusion 
therapy for the treatment of common warts in adults. A total of 90 
immunocompetent adult volunteers with at least 1 wart measuring 2 to 15 mm 
were enrolled between October 1, 2004, and July 31, 2005. Eighty patients 
completed the study. Finally they concluded that the no statistically significant 
difference between duct tape and moleskin for the treatment of warts in an adult 
population. 
Katherine M. Stone et.al., 2004, The treatment of genital warts remains 
frustrating since it is often painful, expensive, and unsuccessful. Moreover, little is 
known about the infectivity and natural history of exophytic genital warts or 
subclinical genital infection with human papillomavirus. The traditional goals of 
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therapy for sexually transmitted diseases—eradication of infection, elimination of 
symptoms, prevention of long-term sequelae, and interruption of transmission—
are currently not attainable for or applicable to genital warts. The medical 
literature from January 1988 to August 1993 was reviewed for recent studies on 
the treatment of exophytic warts. The following treatments were included in the 
reviewed studies: podofilox (which was recently approved by the Food and Drug 
Administration), podophyllin, cryotherapy, topical 5-fluorouracil, intralesional 
interferon, systemic interferon, and laser surgery. 
Stephen tyring et.al., 1998, Published the article about the treatment of wart by 
the application of o.5% podophyllox topical cream and demonstrated the effective 
inhibition of pappiloma virus. 
MD Malison et.al., 1994, Demonstrated, that autogenous vaccine is an effective 
form of immunotherapy for condyloma acuminatum, a double-blind cross-over 
study was carried out on 34 patients, in which autogenous wart vaccine was 
compared with a placebo vaccine identically prepared from each patient's own 
normal skin. Finally they concluded that autogenous vaccine are more effective 
treatment for warts. 
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2.2 LITERATURE REVIEW OF PHYTOSOME 
Varsha Kashaw et.al., 2011, Liver an imperative organ has a crucial in the 
metabolism of xenobiotics that causes it to succumb to numerous hepatic diseases. 
Synthetic drugs exploited in the treatment of liver diseases are incompetent and 
may sometimes lead to serious side-effects. In this context, herbal therapy has 
emerged as a proficient approach with good values in treating hepatic diseases. 
Medicinal plants may serve as a vital source of potentially useful new compounds 
for the development of effective therapy to combat a variety of liver problems. 
Many herbs have been proven to be effectual as hepatoprotective agents while 
many more are claimed to be hepatoprotective but lack any such scientific 
evidence to support such claims. Developing a satisfactory herbal therapy to treat 
severe liver diseases requires systematic investigation of properties such as 
antiviral action (Hepatitis B, Hepatitis C), anti-hepatotoxicity (antioxidants), 
stimulation of liver regenerationand choleretic activity. Formulation of herbal 
medicines with  standards of safety and efficacy can revitalize treatment of liver 
disorders. The focus of this review is to elucidate the concept of hepatotoxicity, 
including its causes, pathogenesis and prevention. And he concluded that the 
scope of herbal plants as well as novel delivery systems like liposomes and 
phytosomes for the treatment of hepatotoxicity and liver related disorders. 
Rahila ahmad pathan et.al., 2011, Prepared a gymnemic acid-phospholipid 
complex (GPC) formulation in attempt to enhance the lipophilicity and to 
characterize the new developed formulation. Gymnemic acid (GA), due to its 
water soluble complex and large structure, restrict permeation across biological 
membrane causes poor bioavailability by oral route. To improve the 
bioavailability and prolong its duration in body system, its phospholipid 
complexes were prepared by a simple and reproducible method. GPC was 
formulated by mechanical dispersion method. Using aqueous ethanol as a reaction 
medium, GA and phospholipids were resolved into the medium, after the solvent 
was removed under vacuum condition, GPC was formed. In this new formulation, 
complex formation was confirmed by carrying out by FTIR, 1H-NMR, XRD, 
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DSC, and microscopical studies. Solubility and in vitro studies were carried out to 
ascertain the solubility and dissolution pattern of free and complexed GA. Content 
of GA in GPC was found 96.27% (w/w). FTIR, 1H NMR, DSC and XRD data 
confirmed the formation of phospholipid complex. n-Octanol solubility was 
altered for free GA and GPC, 8.6 µg to 137 µg/ml. Unlike the free GA this 
showed a burst and rapid drug release, GPC showed sustained release at the end of 
120 minutes of dissolution study in phosphate buffer. Microscopy also shows the 
entrapment of GA in the lipid core showing complex structure, which is supported 
by change in surface morphology of GA when complexed with phospholipid. 
Hence he concluded that, findings demonstrate that complexing GA with 
phospholipids results in better n-Octanol solubility, enhance lipophilicity, and 
altered physicochemical profile compared to free GA which can lead to improved 
biological effects. 
Sunitha manthena et.al., 2010, Studied the Phytoconstituents, despite having 
excellent bioactivity in vitro, demonstrate less or no in vivo actions due to their 
poor lipid solubility or improper molecular size or both, resulting in poor 
absorption and poor bioavailability. Lipid solubility and molecular size are the 
major limiting factors for molecules to pass the biological membrane and to be 
absorbed systematically following oral or topical administration. Some 
phytoconstituents are destroyed in the gastric environment when taken orally. The 
term "phyto" means plant, while "some" means cell-like. Therefore, phytosome is 
a "phytophospholipid complex" resembling a small cell. Phytosomes are produced 
by a patented process whereby standardized plant extracts or their constituents are 
bound to phospholipids, mainly phosphatidylcholine, producing a lipid-
compatible molecular complex. Phytosomes exhibit a better pharmacokinetic and 
pharmacodynamic profile than conventional herbal extracts. And concluded that, 
The phytosome technology markedly enhances the bioavailability of 
phytomedicine and has effectively enhanced the bioavailability of many popular 
herbal extracts, including Milk thistle, Ginkgo biloba, Grape seed, Green tea, 
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Hawthorn, Ginseng etc., and can be developed for various therapeutic uses or 
dietary supplements 
Javed et.al., 2010, The present article dwells in reviewing critically the patents 
published mainly on the new emerging trends and techniques for increasing the 
bioavailability of silymarin, the polyphenolic fraction obtained from the seeds of 
Silybum marianum. The use of this herb for treating various ailments like 
hepatitis, cirrhosis, jaundice, mushroom and toxin poisoning is well known. But 
the potential use of this herbal drug is limited due to the poor absorption and poor 
bioavailability after oral administration. The belief that the natural medicines are 
much safer than synthetic drugs, has gained popularity in recent years and led to 
tremendous growth of phytopharmaceutical usage and thus the need of improving 
the bioavailability by various means like complexation, derivatization, 
solubilization, targeted delivery, controlled delivery and many other 
miscellaneous techniques. They concluded that phyto phospholipid complex are 
showing better pharmacokinetic profile than other bioavailability enhancement 
technique for phytoconstituent 
J. Naga Sowjanya et.al., 2010, Carried out the research in natural medicinal 
plants. Several plant extracts and phytoconstituents, despite having excellent 
bioactivity in vitro demonstrate less or no in vivo actions due to their poor lipid 
solubility or improper molecular size or both, resulting poor absorption and poor 
bioavailability. So, much work has been directed towards the development of new 
concept in herbal delivery system i.e., “Phytosomes” which are better absorbed, 
utilized and as a result produce better results than conventional herbal extracts 
owing to the presence of phosphatidylcholine which likely pushes the 
phytoconstituent through the intestinal epithelial cell outer membrane, 
subsequently accessing the bloodstream. And he concluded that the Phytosomes 
have improved pharmacokinetic and pharmacological parameter which in result 
can advantageously be used in the treatment of the acute and chronic liver disease 
of toxic metabolic or infective origin or of degenerative nature. It can also be used 
Literature Review   
 
‐54‐ 
 
in anti-inflammatory activity as well as in pharmaceutical and cosmetic 
compositions. 
 
Rajendra Awasthi et.al.,2010,  Done the research on phytosomal preparation are 
compared with conventional herbal preparations about their bioavailability and 
pharmacokinetic and pharmacodynamic properties. Thorough study of literature 
different phytosome products has demonstrated significant therapeutic or health 
promoting properties when compared with the conventional plant extracts. 
Phytosomes can be developed for different therapeutic purposes like 
hepatoprotective, cardiovascular, liver diseases. 
 
Sapna malviya et.al., 2009, Phytosome is usually a flavonoids molecule linked 
with phosphatidylcholine molecule. A bond is formed between the two molecules, 
creating a hybrid molecule. This highly lipid-miscible hybrid bond is better suited 
to merge into the lipid phase of the enterocyte's outer cell membrane and from 
there into the cell, finally reaching the blood. Phosphatidylcholine is not merely a 
passive "carrier" for the bioactive flavonoids of the phytosomes, but is itself a 
bioactive nutrient with documented clinical efficacy for diseases, including 
alcoholic hepatic steatosis, drug-induced liver damage, hepatitis, Alzheimer's, 
brain aging, skin diseases, cardiovascular diseases such as congestive heart failure 
and it also act as an effective antioxidant. And finally he concluded that 
phytosome are showing better pharmacokinetic profile for various diseased 
conditions. 
 
Mukesh S. Sikarwar et.al., 2008, Formulated the Marsupsin–phospholipid 
complex (M–P Complex) in attempt to increase the bioavailability of marsupsin 
and to characterize this new formulation along with its evaluation. Marsupsin–
phospholipid complex was formulated by mechanical dispersion method. In this 
new formulation, complex formation was confirmed by carrying out transmission 
electron microscopy (TEM), IR, 1H-NMR and RP-HPLC analysis. TEM showed 
M–P Complex diameter range of 0.05–0.5 µm. The entrapment efficiency of M–P 
Complex was found to be 44%. In vitro release study revealed its first order 
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release profile. Mean blood serum concentration vs time curve of marsupsin was 
of first order after oral administration of M–P Complex in albino rabbits which 
clearly showed remarkably increased bioavailability of M–P Complex than 
standardized marsupsin. The average value of Cmax and Tmax of M–P Complex 
were found to be 3.02 mg/ml and 10.2 h, respectively. Hence the findings 
demonstrate that complexing marsupsin with phospholipids results in better oral 
bioavailability and improved biological response than free form of standardized 
marsupsin. 
 
Amit gupta et.al., 2007, Bioavailability of lipophilic drugs when administered 
orally as solid dosage form is significantly low. There are usually several factors 
responsible for this, but a particularly widespread problem is poor absorption due 
to slow and/or incomplete drug dissolution in the lumen of the gastrointestinal 
tract. The phytosomes according to the invention have a marked lipophilic 
character and unexpectedly improve oral/topical absorption of complexed and 
consequently show improved specific activity in the various pharmacological tests 
made by experimental methods. The phytosome process intensifies herbal 
compounds by improving absorption, increasing bioavailability and enhancing 
delivery to the tissues. Finally concluded that phytosome technology enables cost 
effective delivery and synergistic benefits form the phospholipid nutraceuticals 
intrinsic to life. 
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NEED FOR THE PRESENT STUDY 
 Wart is a solid outgrowth on the epidermis Caused by viral infection, 
specifically by one of the many types of Human papilloma virus. There are 10 
varieties of warts,  They typically disappear after a few months but can last for 
years and can reoccur. 
 Wart treatment should be harmless to normal skin surface, painless, 
inexpensive and should not form any scar on the treated surface. Also the drug 
should act on the affected cells only with avoidance of recurrence. 
 Currently available wart treatment procedures and wart removal 
procedures are complicated and should not satisfy the above requirements. The 
allopathic treatments are more painful and the recurrence of infection is possible. 
 Based on the above reasons Complementary Alternative System of 
Treatments are selected to treat Wart effectively with the plant Thuja occidentalis 
extract. The cytotoxic property of Thuja occidentalis act on the thickened layer of 
stratum corneum (hyperkeratosis), thickening of the stratum spinosum 
(acanthosis) and thickening of the stratum granulosum. It enhances the immune 
system by stimulating T-lymphocytes and increasing interleukin-2 production.  It  
reduces the size of wart.    
 Thus, the need for the present study is to encapsulate the Thuja 
occidentalis  extract in to Phytosome for effective targeting of wart. 
 
WHY PHYTOSOME? 
 The phosphatidyl choline and cholesterol increases the fluidity and 
permeability of skin surfaces. 
 Inclusion of cholesterol in the preparation of phytosome has been 
demonstrated to alter the properties of phytosome and markedly decreasing the 
efflux of entrapped solid. Since decreasing efflux by even 1/3 would both increase 
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the peak concentration and the half time in the plasma by 3 fold, greatly 
enhancing the therapeutic effect of this antiwart treatment. 
 Phosphatidyl choline has greatly impacted the drug delivery technology. 
The very first and most important advantage of phospholipid based vesicular 
system is the compatibility of phospholipids with membrane of human either 
internal membrane as well as skin (external membrane). For a drug to be absorbed 
and distributed into organs and tissues and eliminated from the body, it must pass 
through one or more biological membranes/ barriers at various locations. Such a 
movement of drug across the membrane is called as drug transport. For the drugs 
to be delivered to the body should cross the membranous barrier. Either it would 
be from oral route or topical/transdermal route. Therefore the phospholipid based 
carrier systems are of considerable interest in this era. A number of drug delivery 
systems are based entirely on Phosphatidyl choline such as Liposome, Ethosome, 
Phytosome, Transferosomes, and Nanocochelates. 
 The targeted delivery of Phytosomal formulation of Thuja occidentalis 
containing the constituent  flavonoid is  potent, so it is more suitable to deliver by 
targeted drug delivery. 
 The active constituents may be accumulated in the skin by this technique. 
 The Phytosome are formulated by the formation chemical bond between 
the extract and phosphatidyl choline, thus the phytosome are more stable than 
liposome.        
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PLAN OF WORK 
1.EXTRACTION AND IDENTIFICATION 
9 Collection of plant 
 
9 Authentification of plant  
 
 
 Drying and Powdering of Leaves 
 Selection of solvents 
 Extraction by Soxylation 
 
9 Phytochemical Analysis 
9 Characterization  of  Extract  
 Absorption maxima  
 Solubility tests 
 FT- Infrared study 
 Calibration curve  
 
 
 
3.MATERIALS AND EQUIPMENTS USED 
4.FABRICATION AND CHARACTERIZATION PHYTOSOMAL DDS 
  a. Fabrication of Phytosome  
 Solvent evaporation technique 
 Optimization of various parameters in Phytosomal formulation  
b. Compatibility studies 
 FT Infra  red spectrum 
c. Characterization of Phytosome  
 Shape – SEM 
 
 Size 
 
 Particle Size Distribution 
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 Drug Entrapment efficiency 
 
 Drug content analysis 
d. In-vitro studies 
 In-vitro diffusion study-Drug release profile 
 
6. INCORPORATION OF SELECTED FORMULATION into GEL BASE 
a. Physicochemical evaluation 
b. In-vitro diffusion study of Phytosomal Gel- release profile 
c. Comparison of Extract Phytosome, Phytosomal Gel with marketed  
    Thuja Gel 
d. Stability testing 
e. Animal studies – Skin irritation studies 
 
7. RESULTS AND DISCUSSION 
8. SUMMARY AND CONCLUSION 
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MATERIALS AND EQUIPMENTS  
 
List of Materials used for Phytosomal preparation 
 
S.No Materials Used Manufacturer 
1 Thuja occidentalis Local vendors, Trichy. 
2 Cholesterol Sigma-Aldrich Cheme, 
Germany. 
3 Phosphatidyl choline Qualigens  fine chemicals, 
Mumbai. 
4 Methanol Sigma-Aldrich cheme, 
Germany. 
5 Chloroform Himedia, Mumbai. 
6 Pet ether Ranbaxy, Mumbai. 
7 Ethanol Ranbaxy, Mumbai. 
8 Sodium alginate Sigma-Aldrich cheme, 
Germany. 
9 Distilled water Ranbaxy, Mumbai. 
10 Triethanolamine Sigma-Aldrich cheme, 
Germany. 
11 Triton-X100 Qualigens, Mumbai. 
12 Potassium dihydrogen 
ortho phosphate 
Ranbaxy , Mumbai. 
13 Disodium hydrogen 
phosphate 
Ranbaxy , Mumbai. 
14 Sodium chloride Nice chemicals, Cochin. 
   
 Table-1  
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List of Equipments Used for Phytosomal preparation 
 
S.No Equipments Manufacturer 
1 Rotary Flask Evaporator Equitron, Medica Instrument 
Mfg co, Mumbai 
2 Ultra sonicator Vibronics, Mumbai 
3 UV-Spectrophotometry  Shimadzu 1700, Japan 
4 Electronic Balance Sartorius, Germany 
5 SEM Hitachi, Model S-3000 H, Japan 
6 FT-IR Perkin elmer, USA 
7 Centrifuge Remi 
8 pH meter Elico L1120, A.P, India 
9 Magnetic stirrer Remi, Gujarat. 
10 Environment stability 
testing chamber 
Heco Environment Chamber, 
Germany 
 
Table -2 
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CHAPTER -3 
3.1 PLANT AND EXCIPIENTS PROFILE 
 
THUJA OCCIDENTALIS 
 
Figure-1 
DESCRIPTION 
  Family      : Cupressaceae 
 Synonym     : Tree of Life, Yellow Cedar, American  
     Arborvitae    
Genus      : Thuja 
 Species    : T. occidentalis 
 Botanical source :           Thuja occidentalis 
 Active constituents : Flavonoids, Essential oil (thujone), Volatile  
     oil (0.4- 1%); the main compound is thujone  
     (both alpha-thujone and beta-thujone, up to  
     65% of the total oil), together with   alpha – 
     pinene, camphor, borneol and fenchone.  
Also the constituens are sesquiterpenes,  
flavonoids and polysaccharides 
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The name "Thuja" was given to this group of trees by the Swedish botanist 
Linnaeus in 1753; it comes from the Greek word thuo, which means "to sacrifice," 
as cedar wood was often burned with animal sacrifices by the ancients to add a 
pleasing aroma to the fire[1]. 
Thuja occidentalis is native to North America and grows in dense forests 
in southeastern Canada and the northeastern United States.  
American cedar trees grow to a height of about 60 feet (18.2 m), with 
trunks between 12 and 24 in (31 and 61 cm) in diameter.  
They are slow-growing trees, and prefer wet soils. The leaves of the 
American cedar are bright green, opposite leaves that resemble overlapping scales, 
and give off a fragrant odor when crushed. The tiny yellow or greenish flowers 
appear between April and July. American cedar cones are pale green when young 
but turn a pale reddish-brown color as they mature. 
Thuja is also the name for a homeopathic remedy made from Thuja 
occidentalis. 
Distribution 
 Thuja occidentalis is native to Manitoba east throughout the Great Lakes 
Region and into Québec, Vermont, New Hampshire, Maine, Prince Edward 
Island, New Brunswick, and Nova Scotia. Isolated populations exist to the south 
in Massachusetts, Connecticut, Ohio, Kentucky, Tennessee, North Carolina, 
Pennsylvania, Maryland, Virginia, and West Virginia. 
Genaral Uses 
9 Cedar trees in general have a long history of use for various herbal 
remedies and aromatherapy preparations  
9 In Western herbal medicine, cedar leaf oil was used as an 
emmenagogue, abortifacient, vermifuge, diuretic, and digestive aid 
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9 It was applied externally to relieve the pains of arthritis and 
rheumatism, to treat external fungal infections of the skin (ringworm 
and thrush), and to remove anal or genital warts  
9 Native Americans used cedar leaf preparations to relieve headache and 
to prevent scurvy 
9 Cedar leaves and twigs are in fact rich in vitamin C , and it was their 
effectiveness in preventing or treating scurvy that led to the tree's being 
called arbor vitae or tree of life 
9 In addition, recent research has shown that extracts prepared from 
either Thuja occidentalis or Thuja plicata do in fact have antiviral, 
anti-inflammatory, and antibacterial properties 
9 A group of German researchers reported in 2002 that an extract 
prepared from cedar leaf, alcohol, and water inhibits the reproduction 
of influenza virus type A[2] 
9 Another group of Japanese researchers reported in 2003 that several 
compounds isolated from the stem bark of Japanese cedar appear to 
have significant antitumor activity 
9 In traditional Chinese medicine, the leaves and stems of Thuja 
orientalis are used to treat nervous disorders, insomnia, and heart 
palpitations, as well as to stop hemorrhages and bring down fevers 
9 Traditional Chinese physicians also make a preparation of fresh cedar 
leaves steeped for seven days in a 60% alcohol solution to promote 
hair growth. The mixture is rubbed on the bald spots three times daily 
9 The homeopathic preparation known as Thuja is made from the leaves 
of Thuja occidentalis, and is given to treat soft or bleeding warts on the 
chin, genitals, or anus 
9 The most widely used homeopathic materia medica, or reference book, 
also recommends Thuja for headaches, vertigo, emotional depression 
and restlessness, pain or itching in the scalp 
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9 In aromatherapy, Thuja occidentalis is used for anxiety, asthma, 
bronchitis, and head colds. Some aromatherapists also recommend 
cedar leaf oil for treating acne and dandruff  
Available Preparations 
  Most products used in Western medicine and aromatherapy that contain 
cedar oil are made with oil from the leaves and twigs of Thuja occidentalis.  
 These parts of the tree yield about 1% volatile oil, which is about 65% 
thujone. The other components include fenchone, borneol, limonene, pinene, 
camphor, myrcene, a flavonoid known as thujin, and tannin. 
 The oil is extracted from the leaves by a process of steam distillation, 
cooled in an indirect contact heat exchanger, filtered and stored in barrels for 
distribution to wholesalers. 
 For internal use as a diuretic or expectorant, Western herbalists 
recommend taking 1/4-teaspoonfull of liquid extract of cedar leaf in a glass of 
water three to six times a day. Alternately, an infusion can be prepared by adding 
1 ounce of fresh cedar leaves to a pint of boiling water. The infusion is taken cold 
in 1-tebspoonfull doses every three to six hours[3]. 
 Homeopathic preparations of Thuja include pills, granules, and liquid 
dilutions, in potencies ranging from 3X to 50M. 
  Tinctures of Thuja are sold only to homeopathic practitioners, Boiron, a 
well-known manufacturer of homeopathic remedies, Also offers, Thuja ointment 
for the treatment of external warts 
Interactions 
 No interactions between products containing cedar oil and prescription 
medications have been reported as of early 2004. 
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Dose 
 Oral dose upto 1.25 mg/kg is harmless in human. which is equal to 85 mg 
in 150 pound person[54]. 
 Single daily dose 75mg is safe in human. 
 Topical dosage are much higher. The content of Thuja extract is present in 
most skin care products is usually less than 1%. Thuja extract contains 2.4% 
thujone, Thus most skin care products contain 0.024% thujone[5].  
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3.2 CHOLESTEROL 
Structure of Cholesterol 
 
 
Figure-2 
  
 The name originates from the Greek word chole-(bile) and stereos(solid), 
and the chemical suffix – ol for an alcohol, most of the cholesterol in the body is 
synthesized by the body and some has dietry origin. Cholesterol is more abundant 
in tissue which either synthesize more or have more abundant densely-packed 
membranes, for example, the liver, spinal cord and brain. Cholesterol is also 
considered as sterol (a combination steroid and alcohol)[56]. 
 Since cholesterol is insoluble in blood, it is transported in the circulatory 
system within lipoproteins, complex spherical particles which have an exterior 
composed mainly of water soluble proteins; fats and cholesterol are carried 
internally[58]. 
Nonproprietary Names 
  
 BP  :  Cholesterol 
 JP  :  Cholesterol 
 PhEur  :  Cholesterolum 
 USPNF :  Cholesterol 
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Synonyms 
 Cholesterin 
 Cholesterolum. 
 
Chemical Name and CAS Registry Number 
 
 Cholest-5-en-3ßY-ol [57-88-5] 
 
Functional Category 
 
 Emollient 
 Emulsifying agent  
Excretion; 
 Cholesterol is excreted from the liver in bile and reabsorbed from the 
intestine 
Stability and Storage Conditions 
 
 Cholesterol is stable and should be stored in a well-closed container, 
protected from light. 
 
Incompatibilities 
 
 Cholesterol is precipitated by digitonin. 
Applications in Pharmaceutical Formulation or Technology 
 
 Cholesterol is used in cosmetics and topical pharmaceutical formulations 
at concentrations of 0.3–5.0% w/w as an emulsifying agent. It imparts water-
absorbing power to an ointment and has emollient activity[57]. 
 
 Cholesterol also has a physiological role. It is the major sterol of the higher 
animals, and it is found in all body tissues, especially in the brain and spinal cord. 
It is also the main constituent of gallstones[56] 
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Properties of cholesterol 
 
IUPAC name (10R,13R)-10,13,-dimethyl-17-(6-methylheptan-2-yl)-
2,3,4,4,7,8,9,11,14,15,16,17,-dodecahydro-1H-
cyclopenta[a] phenanthren-3-ol 
CAS numbers [57-88-5] 
Molecular formula C27H46O 
Molar mass 386.654 
Appearance White crystalline powder 
Melting point 148◦C-150◦C 
Boiling point 360◦C 
Solubility in water 0.095 mg/L (30◦C) 
Table -3 
 Sources 
 Cholesterol is found in animal fats. All food containing animal fats 
contains cholesterol; food not containing animal fats either contains no cholesterol 
or negligible amounts major dietary sources of cholesterol include egg yolks, beef, 
poultry and shrimp.  
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Synonyms 
 E322; egg lecithin; LSC 5050; LSC 6040; mixed soybean phosphatides; 
ovolecithin; Phosal 53 MCT; Phospholipon 100 H; soybean lecithin; soybean 
phospholipids; Sternpur; vegetable lecithin. 
  
Chemical Name and CAS Registry Number 
 
 Lecithin [8002-43-5] 
  
The chemical nomenclature and CAS Registry numbering of lecithin is 
complex. The commercially available lecithin, used in cosmetics, 
pharmaceuticals, and food products, is a complex mixture of phospholipids and 
other materials. However, it may be referred to in some literature sources as 1,2-
diacyl-sn-glycero-3-phosphocholine (trivial chemical name, phosphatidylcholine). 
This material is the principal constituent of egg lecithin and has the same CAS 
registry Number.  
 
Typical Properties 
  
 Density: 
  0.97 g/cm3 for liquid lecithin; 
  0.5 g/cm3 for powdered lecithin. 
 Iodine number: 
  95–100 for liquid lecithin; 
  82–88 for powdered lecithin. 
  
 Saponification value: 196 
 
Solubility 
Lecithins are soluble in aliphatic and aromatic hydrocarbons, halogenated 
hydrocarbons, mineral oil, and fatty acids. They are practically insoluble in cold 
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vegetable and animal oils, polar solvents, and water. When mixed with water, 
however, lecithins hydrate to form emulsions. 
 
Empirical Formula and Molecular Weight 
 
 The USPNF 23 describes lecithin as a complex mixture of acetone-
insoluble phosphatides that consists chiefly of phosphatidyl choline, phosphatidyl 
ethanolamine, phosphatidyl serine, and phosphatidyl inositol, combined with 
various amounts of other substances such as triglycerides, fatty acids, and 
carbohydrates as separated from a crude vegetable oil source. The composition of 
lecithin (and hence also its physical properties) varies enormously depending upon 
the source of the lecithin and the degree of purification. Egg lecithin, for example, 
contains 69% phosphatidyl choline and 24% phosphatidyl ethanolamine, while 
soybean lecithin contains 21% phosphatidyl choline, 22% phosphatidyl 
ethanolamine, and 19% phosphatidyl inositol, along with other components. 
 
Functional Category 
  
 Emollient 
 Emulsifying agent 
 Solubilizing agent. 
 
Applications in Pharmaceutical Formulation or Technology 
 
 Lecithins are used in a wide variety of pharmaceutical applications, They 
are also used in cosmetics  and food products. 
 
Concentration of Routes  
 
Use Concentration (%) 
Aerosol inhalation 0.1 
IM injection 0.3–2.3 
Oral suspensions 0.25–10.0 
 
Table - 4 
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Lecithins are mainly used in pharmaceutical products as dispersing, 
emulsifying, and stabilizing agents and are included in intramuscular and 
intravenous injections, parenteral nutrition formulations, and topical products such 
as creams and ointments. 
  
 Lecithins are also used in suppository bases, to reduce the brittleness of 
suppositories, and have been investigated for their absorption-enhancing 
properties in an intranasal insulin formulation. Lecithins are also commonly used 
as a component of enteral and parenteral nutrition formulations. 
 
 There is evidence that phosphatidyl choline (a major component of 
lecithin) is important as a nutritional supplement to fetal and infant development. 
Furthermore, choline is a required component of FDA-approved infant formula. 
Other studies have indicated that lecithin can protect against alcohol cirrhosis of 
the liver, lower serum cholesterol levels, and improve mental and physical 
performance. 
  
 Liposomes in which lecithin is included as a component of the bilayer 
have been used to encapsulate drug substances; their potential as novel delivery 
systems has been investigated. This application generally requires purified 
lecithins combined in specific proportions. Therapeutically, lecithin and 
derivatives have been used as a pulmonary surfactant in the treatment of neonatal 
respiratory distress syndrome. 
 
Stability and Storage Conditions 
  
 Lecithins decompose at extreme pH. They are also hygroscopic and 
subject to microbial degradation. When heated, lecithins oxidize, darken, and 
decompose. Temperatures of 160– 180°C will cause degradation within 24 hours. 
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 Fluid or waxy lecithin grades should be stored at room temperature or 
above; temperatures below 10°C may cause separation. All lecithin grades should 
be stored in well-closed containers protected from light and oxidation. Purified 
solid lecithins should be stored in tightly closed containers at subfreezing 
temperatures. 
 
Incompatibilities 
  
 Incompatible with esterases owing to hydrolysis. 
 
Safety 
 Lecithin is a component of cell membranes and is therefore consumed as a 
normal part of the diet. Although excessive consumption may be harmful, it is 
highly biocompatible and oral doses of up to 80 g daily have been used 
therapeutically in the treatment of tardive dyskinesia.When used in topical 
formulations, lecithin is generally regarded as a nonirritant and nonsensitizing 
material. The Cosmetic Ingredients Review Expert Panel (CIR) has reviewed 
lecithin and issued a tentative report revising the safe concentration of the material 
from 1.95% to 15.0% in rinse-off and leave-in products. They note, however, that 
there are insufficient data to rule on products that are likely to be inhaled. 
 
Handling Precautions 
 
Observe normal precautions appropriate to the circumstances and quantity 
of material handled. Lecithins may be irritant to the eyes; eye protection and 
gloves are recommended. 
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3.4 SODIUM ALGINATE 
 
Nonproprietary Names 
  
 BP  : Sodium alginate 
 PhEur   :  Natrii alginas 
 USPNF :  Sodium alginate 
 
Synonyms 
 Algin; alginic acid, sodium salt; E401; Kelcosol; Keltone; Protanal; 
sodium polymannuronate. 
 
Chemical Name and CAS Registry Number 
 Sodium alginate [9005-38-3] 
 
Empirical Formula and Molecular Weight 
 
 Sodium alginate consists chiefly of the sodium salt of alginic acid, which 
is a mixture of polyuronic acids composed of residues of D-mannuronic acid and 
L-guluronic acid. The block structure and molecular weight of sodium alginate 
samples has been investigated 
 
Functional Category 
 Stabilizing agent; suspending agent; tablet and capsule disintegrant; tablet 
binder; viscosity increasing agent. 
 
Applications in Pharmaceutical Formulation or Technology 
 
 Sodium alginate is used in a variety of oral and topical pharmaceutical 
formulations. In tablet formulations, sodium alginate may be used as both a binder 
and disintegrant; it has been used as a diluent in capsule formulations. Sodium 
alginate has also been used in the preparation of sustained-release oral 
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formulations since it can delay the dissolution of a drug from tablets, capsules, 
and aqueous suspensions. 
 
 In topical formulations, sodium alginate is widely used as a thickening and 
suspending agent in a variety of pastes, creams and gels and as a stabilizing agent 
for oil-in-water emulsions. Recently, sodium alginate has been used for the  
aqueous microencapsulation of drugs, in contrast with the more conventional 
microencapsulation techniques which use organic solvent systems. It has also 
been used in the formation of nanoparticles. 
 
 The adhesiveness of hydrogels prepared from sodium alginate has been 
investigated and drug release from oral mucosal adhesive tablets, and buccal gels, 
based on sodium alginate have been reported. Other novel delivery systems 
containing sodium alginate include ophthalmic solutions that form a gel in situ 
when administered to the eye; an in situ forming gel containing paracetamol for 
oral administration; and a freeze-dried device intended for the delivery of bone-
growth factors Hydrogel systems containing alginates have also been investigated 
for delivery of proteins and peptides. 
 
 Therapeutically, sodium alginate has been used in combination with an H2-
receptor antagonist in the management of gastro esophageal reflux, and as a 
haemostatic agent in surgical dressings. Alginate dressings, used to treat exuding 
wounds, often contain significant amounts of sodium alginate as this improves the 
gelling properties. Sponges composed of sodium alginate and chitosan produce a 
sustained drug release and may be useful as wound dressings or as tissue 
engineering matrices. Sodium alginate is also used in cosmetics and food 
products;  
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Concentration in formulations   
 
Use Concentration (%) 
Pastes and creams 5–10 
Stabilizer in emulsions 1–3 
Suspending agent 1–5 
Tablet binder 1–3 
Tablet disintegrant 2.5–10 
    
Table - 5 
Description 
 Sodium alginate occurs as an odorless and tasteless, white to pale 
yellowish-brown colored powder. 
 
Typical Properties 
  
Acidity/alkalinity 
pH 7.2 for a 1% w/v aqueous solution. 
 
Solubility 
   
Practically insoluble in ethanol (95%), ether, chloroform, and 
ethanol/water mixtures in which the ethanol content is greater than 30%. 
Also, practically insoluble in other organic solvents and aqueous acidic 
solutions in which the pH is less than 7. Slowly soluble in water, forming a 
viscous colloidal solution. 
 
Viscosity (dynamic) 
 
Various grades of sodium alginate are commercially available that 
yield aqueous solutions of varying viscosity. Typically, a 1% w/v aqueous 
solution, at 20°C, will have a viscosity of 20–400 m Pas (20–400 cP). 
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Viscosity may vary depending upon concentration, pH, temperature, or the 
presence of metal ions. Above pH 10, viscosity decreases. 
 
Stability and Storage Conditions 
  
 Sodium alginate is a hygroscopic material, although it is stable if stored at 
low relative humidities and a cool temperature. 
 
 Aqueous solutions of sodium alginate are most stable at pH 4–10. Below 
pH 3, alginic acid is precipitated. A 1% w/v aqueous solution of sodium alginate 
exposed to differing temperatures had a viscosity 60–80% of its original value 
after storage for 2 years. Solutions should not be stored in metal containers. 
 
 
 Sodium alginate solutions are susceptible on storage to microbial spoilage, 
which may affect solution viscosity. Solutions are ideally sterilized using ethylene 
oxide, although filtration using a 0.45 µm filter also has only a slight adverse 
effect on solution viscosity. Heating sodium alginate solutions to temperatures 
above 70°C causes depolymerization with a subsequent loss of viscosity. 
Autoclaving of solutions can cause a decrease in viscosity, which may vary 
depending upon the nature of any other substances present. Gamma irradiation 
should not be used to sterilize sodium alginate solutions since this process 
severely reduces solution viscosity. 
 
 
 Preparations for external use may be preserved by the addition of 0.1% 
chlorocresol, 0.1% chloroxylenol or parabens. If the medium is acidic, benzoic 
acid may also be used. The bulk material should be stored in an airtight container 
in a cool, dry place. 
 
Incompatibilities 
  
 Sodium alginate is incompatible with acridine derivatives, crystal violet, 
phenylmercuric acetate and nitrate, calcium salts, heavy metals, and ethanol in 
concentrations greater than 5%. Low concentrations of electrolytes cause an 
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increase in viscosity but high electrolyte concentrations cause salting-out of 
sodium alginate; salting-out occurs if more than 4% of sodium chloride is present. 
 
Safety 
 Sodium alginate is widely used in cosmetics, food products, and 
pharmaceutical formulations, such as tablets and topical products, including 
wound dressings. It is generally regarded as a nontoxic and nonirritant material, 
although excessive oral consumption may be harmful. A study in five healthy 
male volunteers fed a daily intake of 175 mg/kg bodyweight of sodium alginate 
for 7 days, followed by a daily intake of 200 mg/kg body-weight of sodium 
alginate for a further 16 days, showed no significant adverse effects. 
 
 The WHO has not specified an acceptable daily intake for alginic acid and 
alginate salts as the levels used in food do not represent a hazard to health. 
 
 Inhalation of alginate dust may be irritant and has been associated with 
industrial-related asthma in workers involved in alginate production. However, it 
appears that the cases of asthma were linked to exposure to seaweed dust rather 
than pure alginate dust. 
 
Handling Precautions 
  
 Observe normal precautions appropriate to the circumstances and quantity 
of material handled. Sodium alginate may be irritant to the eyes or respiratory 
system if inhaled as dust;  Eye protection, gloves, and a dust respirator are 
recommended. Sodium alginate should be handled in a well-ventilated 
environment. 
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Drying and Powdering  of Plant 
 The fresh leaves were spreaded under shadow place to remove the 
chlorophyll content in the leaves for seven days. And the colour of the leaves were 
evaluated in between days. After the shadow drying process the leaves of Thuja 
occidentalis were free from chlorophyll content. 
 The shadow dried leaves were collected and it was made to grind to get 
coarse powder for effective  soxhlation. To avoid the fine powder formation for 
good yield value from the extraction. The coarse powder of Thuja occidentalis 
leaves were packed for soxhlation. 
 The coarse was packed in a thimble, and it was placed over the round 
bottom flask and above the thimble condenser placed for condensing evaporating 
vapour in to the thimble. 
Selection of Solvents 
 Solvents are playing the major role in extraction process. The extractive 
solvents otherwise called as menstrum is generally hydroalcoholic (i.e. a mixture 
of water and alcohol).  
 Based on the active constituents of Thuja occidentalis, solvents like pet 
ether and ethanol were selected. Pet ether was selected to remove waxy oil 
constituents from the plant.  
 The hydroalcoholic solvent ethanol was selected to extract the active 
constituent of the flavanoid is extracted.  
  Extraction by Soxylation 
 Extraction may be defined as a process of removing the soluble active 
principles present in plant tissues from the inactive and insoluble residue by use of 
selective solvents.  
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 To execute continuous hot extraction, a soxhlet apparatus is used. The 
soxhlet apparatus is used for the extraction on a small scale. It consist of a flask, a 
soxhlet extractor and a reflux condenser. The powdered coarse powder of Thuja 
occidentalis placed in a thimble made of filter paper was inserted in to the wide 
tube of the extractor.  
 The solvent pet ether was taken in the flask to remove waxy substances 
from the plant. The solvent was heated and the vapour  arises from the flask was 
get in to the condenser through the side tube and the liquid condensed from the 
vapours drips in to the thimble. The solvent liquid levels slowly rises and during 
this period, fat gets extracted of its soluble constituents.  
 When the level of the liquid reaches the top of the syphon, it gets 
syphoned in to the flask. The suction effect of the syphoning assists permeation of 
the solvent through the plant material. 
 Again, a portion of the solvent from the solution was vapourised leaving 
the constituents in the flask itself and the process mentioned above is repeated. 
And the total oil content along with fatty material from the plant was removed by 
this pet ether extract. And the plant was removed from the thimble and dried in 
open atmosphere. Pet ether from the plant is removed after the plant was ready to 
treat with ethanol to execute the active constituents from the plant.   
 The solvent ethanol was taken in the flask and it was heated. The same 
process was repeated again and again until all the solutes are extracted. The active 
constituents containing extractive liquid was processed with rotary film 
evaporator to remove the solvent ethanol. And the pure extract (i.e. 100% free 
from solvent) was collected from the flask.  
 The extract may contain different active constituents, it was identified with 
the help of infra red studies, chemical tests, solubility test and absorption maxima 
of extract.       
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 The ethanolic crude extract of Thuja occidentalis may contain different 
active compounds. It was identified with the help of infrared spectrum of the 
extract. 
 Absorption maxima (λ max) 
Drug molecule in solution when exposed to light in the visible/ultraviolet 
region of the spectrum absorbs light of particular wave length depending on the 
type of electronic transition associated with the absorption. 
The drug solution (1mg/ml) in phosphate buffer pH 6.8 was taken in the 
cuvette scanned in the range of 230 to 400 nm in a UV spectrophotometer.  It 
exhibits maxima at 361nm.  Therefore, all the further measurements were taken at 
361nm 
Reference standard 
  Thuja occidentalis constituent of flavanoid like quercetin showing the 
maximum absorption peak at 364 nm in the phosphate buffer 6.8 solution[87].  
Flavonoid absorption maxima 
 
Figure- 5 
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Solubility Tests 
 The spontaneous interaction of two or more substances to form a 
homogenous molecular dispersion is called solubility. The solubility of  crude 
extract of Thuja occidentalis was studied in various solvents. The extract of Thuja 
occidentalis (10mg) was suspended separately in a 10ml of different solvents at 
room temperaturein tightly closed test tubes and shaken on wrist action shaker for 
8 hours. The solubility profile of Thuja occidentalis are shown in table-24 
 The approximate solubility of substances are indicated by the descriptive 
term in the accompanying table. 
Solubility standard value 
Descriptive term Parts of solvent required for 1  
part of solute 
Very soluble  Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30  to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10,000 
Practically insoluble or Insoluble Greater than or equal to 10,000 
 
Table- 6 
Caliberation curve for extract 
Preparation of phosphate buffer pH 6.8 
 Phosphate buffer pH 6.8 was prepared according to the following methods 
(I.P.1996).  Disodium hydrogen phosphate (6.8g) was dissolved in 500ml of 
distilled water and sodium hydroxide (1g) was dissolved in distilled water from 
that 224ml of solution was taken and added with above solution and volume was 
made up to 1 liter with distilled water.  The pH was adjusted to 6.8 prior to 
quantitative estimation. 
Materials and Methods  
 
‐86‐ 
 
Preparation of Calibration Curve of Thuja occidentalis in Phosphate buffer 
pH 6.8 
 A stock solution was prepared by dissolving 100 mg of crude ethanolic 
extract of Thuja occidentalis in 100 ml phosphate buffer of pH 6.8. It was further 
diluted to obtain the concentration of 5, 10, 15, 20, 25, 30 microgram of the drug 
per ml.  The absorbances of these solutions were determined at 361 nm using UV 
spectroscopy and given in Figure-8 and Table-25.  
The standard curve was constructed between the absorbance and 
concentration. This standard curve was linearly regressed and statistical parameter 
related it was derived.  
   
 
 
 
 
 
Fabrication and Optimization  
 
‐87‐ 
 
 
FABRICATION OF PHYTOSOME 
 The phytosomal formulation of Thuja occidentalis were prepared by Thin 
Film Hydration Technique using Rotary Film Evaporation method. 
 Appropriate amount of cholesterol and phosphoditylcholine were taken in 
round bottom flask and both were dissolved by addition of 5ml of chloroform and 
5ml of methanol. The flask was rotated at above 1.5cm above a water bath at 60 C 
± 2C under pressure, until all the organic phase evaporated and a thin layer was 
formed on the wall of the round bottom flask.  
 The crude extract of Thuja occidentalis was dissolved in 20 ml of distilled 
water and it was hydrated with dried layers of cholesterol and phosphotidylcholine 
in the round bottom flask. and this mixture again rotated in a water bath at 60 C ± 
2 C for 1 hour.  
 The phytosome vesicle containing Thuja occidentalis were subsequently 
formed, further subject to ultra sonication at 5◦ C to 10◦ C for 15 minutes 
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Phytosome preparation flow chart 
 
 
             
      
 
 
   
    
      
     
 
    
 
 
 
 
  
  
      
 
 
Figure-6 
  
Cholesterol and Lecithin 
Added in round bottom flask 
Addition of Methanol and 
Chloroform 
Organic Solvent evaporated from the 
Flask and slimy layer Formed at the walls of 
the round bottom flask
    Rotated at 60 rpm for 20 mts 
          in water bath at 60 C 
Flask removed from the Rotary Flash 
Evaporator 
Extract was dissolved in water and added in 
thin film in the round Bottom flask 
Flask was rotated again at 60 rpm 
for 45 mts at 60 C 
Extract entrapped with the thin 
film and phytosome are formed 
Sonicated 15 mts for further size 
reduction Phytosomes are stored for 
further evaluation 
 
Phytosomes are stored for further evaluation 
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 The prepared phytosomes were stored in a refrigerator for further 
evaluation. During this fabrication of phytosomal formulation, various  parameters 
were optimized to get a stable formulation. 
OPTIMIZATION PARAMETERS 
The effect of different temperatures was seen on the formation of  
phytosomal vesicles 
Optimization of temperature during Phytosomal preparation 
 
S.No Temperature Observation 
1 Below 60◦ C Irregular shaped vesicles 
2 60◦ C ± 2◦ C Spherical vesicles formed 
3 80◦ C ±2◦C Vesicles are less and irregular 
 
Table-7 
Optimization of  temperature during Ultrasonication 
 
S.No Temperature Observation 
1 5◦  C to 10◦ C Size of vesicles decreases 
2 10◦ C to 20 C Numerous vesicles of Moderate 
Size 
3 Room temperature Large Size Vesicles 
 
Table-8 
Optimization of  Rotating speed 
S.No Rpm Observation 
1 50 ± 5 Clumps 
2 100 ± 5 Spherical vesicles 
3 >100 Irregular shaped vesicles 
 
Table-9  
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Optimization of Amount of Solvent 
 
S.No Amount Of Methanol And 
Chloroform 
Observation 
1 1:2 (5 ml : 10ml) Thick, non uniform film  
2 1:1 (5 ml : 5 ml) Thin uniform film 
3 2:1 (10 ml : 5 ml) Take mmore time, less vesicle 
 
Table- 10 
Effect of hydration liquid on Drug Entrapment Efficiency 
 
S.No Hydration Solvent Observation 
1 0.1 M Hcl Low 
2 Water High entrapment efficiency 
3 PBS 7.4 Medium 
 
Table- 11 
Optimization of  Ultrasonication time 
S.No Time in Minutes Observation 
1 10 Incomplete and large sized vesicles 
2 20 Spherical vesicles 
3 30 Broken vesicles 
 
Table-12 
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Optimization ratio of Drug Vs Cholesterol and Lecithin 
 
 
S.No Formulation Code Drug Cholesterol Lecithin 
1 F1 1 (10 mg) 1.5 (15 mg) 4 (40 mg) 
2 F2 1 (10 mg) 1.5 (15 mg) 5 (50 mg) 
3 F3 1 (10 mg) 1.5 (15 mg) 6 (60 mg) 
 
Table-13 
 
Optimized formula – Trial formulation 
 
S.No Formulati
on Code 
Drug 
(mg) 
Cholester
ol (mg) 
Lecithin (mg) Methanol 
(ml) 
Chloroform 
(ml) 
Water Drug: 
Cholestero
l: Lecithin 
1 F1 10 15 40 5 5 20 1:1.5:4 
2 F2 10 15 50 5 5 20 1:1.5:5 
3 F3 10 15 60 5 5 20 1:1.5:6 
Table-14 
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COMPATIBILITY STUDIES 
 Fourier infrared spectroscopy (FT-IR) was performed with ethanolic 
extract of Thuja occidentalis to find to find any interaction between extract and 
the Excipients. 
 
INFRARED SPECTRAL ASSIGNMENT 
 Infrared spectrum of any compound or drug gives information about the 
groups present in that particular compound. IR spectrum of Thuja occidentalis 
extract was taken out on Perkin Elmer IR Spectrophotometer. Various peaks in IR 
spectrum were interpreted for the presence of different groups. 
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CHAPTER-4 
CHARACTERIZATION OF PHYTOSOME 
Morphological Studies 
 The Phytosomes were subjected to SEM examination for characterizing 
shape and surface morphology 
Scanning Electron Microscopy 
 Phytosomes were characterized by SEM (Hitachi model S-3000 H, Japan). 
The resolution of 3.5nm was used with secondary electron image display. The 
Phytosomes were coated with gold palladium alloy (150-250A) using a sputter 
coater. The coater was operated at 2.2kv, 20MV, 0.1 torr (argon) for 90 sec at an 
accelerating voltage of 15 kv. The results are given in Figure-16 
Particle Size 
 The phytosomes were subjected to microscopic examination (SEM) for 
characterizing size. The results are shown in Figure-17 
Size Distribution of Phytosomes 
 Phytosomes were subjected to Laser Particle Counter (L.P.C) for 
characterizing size distribution of phytosomes. The results are shown in Table-33 
 It shows the particle range of 20-200 nm for optimized formulation. The 
average mean particle size was 100nm. 
Drug Content Analysis 
 Formulated phytosome were centrifuged for 25◦ C at 2500rpm for 30 mts 
to separate pure unentraped phytoconstituent from the formulation 
When free drug was seperated, vesicles were lysed using equal volume of 
Triton-X 100(0.1% vol/vol) and analysed for drug content. The absorbance of the 
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solution was measured by UV spectrophotometer (Shimadzu 1700) at 361nm 
against blank to determine its encapsulation efficacy. The results are shown in 
Table- 35 and Figure- 20 
The drug content of phytosomes was calculated according to the following 
equation. 
                    Actual drug content in Phytosome  
 Drug content =     -------------------------------------------------   X 100 
        Theoretical drug content 
 
Drug Entrapment Efficiency 
 The entrapment was determined by dialysis method. Dialysis membrane 
70 (Himedia, Mumbai, India) was immersed in glyserine overnight before dialysis 
to ensure complete wetting of the membrane. 10 ml of drug loaded vesicles was 
placed in membrane which was tied to one end of the open ended cylinder, which 
was then placed in 500ml distilled water. This receiver medium stirred with a 
magnetic stirrer. The medium was changed with fresh medium at half an hour 
interval for atleast 3 to 5 times to remove unentrapped drug and impurities 
 When free drug was separated, vesicles were lysed using equal volume of 
Triton-100 (0.1% vol/vol) and analysed for drug content. 
 
       Amount of drug released from lysed phytosome 
Drug entrapment efficiency (%) =  -----------------------------------------------  X 100 
     Amount of drug found in sample  
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In Vitro Drug Release Studies 
Cellophane Membrane Treatment 
Cellophane membrane was boiled in the distilled water for 1 hr and 
washed with fresh distilled water for three times and kept in ethanol for 24 hrs.  It 
was washed with distilled water and treated with 0.3% sodium sulphite and 
soaked in distilled water for 2min at 60°C followed by acidified with 0.2% 
sulphuric acid.  Finally the membrane was dipped in boric buffer (pH 9) till it is 
used for permeation study[63]. 
Drug Permeation Studies 
The in vitro release rate of Phytosomes were evaluated by open ended tube 
through the cellophane membrane method using PB pH6.8 as diffusion medium 
up to 12 hours studies.  The cellophane membrane is tided in one end of the tube 
and then immersed in the receptor compartment containing 400ml of PB pH6.8. 
Which was stirred at medium speed and maintained at 37°C±2°C.  Samples were 
withdrawn at regular time intervals and the same volume was replaced by fresh 
diffusion medium. The samples were analyzed using UV – visible 
spectrophotometer (Shimadzu UV1700) set at 361 nm.  
Release Kinetics 
Data obtained from invitro release studies were fitted to various kinetic 
equations. The kinetic models used are zero order equations (Q=k0t), First order 
equation {ln (100 – Q)=ln Q – klt}, Higuchi equation(Q=kt1/2), Hixson and 
crowell model Qt1/3 Vs t and Qt2/3 Vs – Modified root cube equation. Further, to 
find out the mechanism of drug release, first 60% drug release was fitted in 
Korsmeyer and peppas equation (Q=kptn). where, Q is the percent of the drug 
release at time t and k0 and kt are the coefficients of the equations and n is the 
release exponent. The n value is used to characterize different release mechanism. 
 The order of drug release can be assessed by graphical treatment of drug 
release data. 
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 A plot of Cumulative % drug release versus time would be linear if the 
drug release follows zero order (ie. Concentration independent release). 
 A plot of log of % remaining drug versus time would be linear, if the drug 
release follows first order (ie. Concentration dependent release) 
 The linear equation for zero order drug release plot is: 
Ct  =  C0 – Kt 
Where,  
Ct  =  concentration remaining at time t, 
  Co =  original concentration, 
  t  =  time, 
  K  =  release rate 
 The linear equation for first order release plot is 
     logC0Kt  
   Log C= ------------ 
       2.303 
 A matrix device as the name implies, consists of drug dispersed 
homogeneously through out a polymer matrix. 
 In this model, drug in the out side layer exposed to the bathing solution is 
dissolved first and than diffuses out of the matrix. This process continues with the 
interface between the bathing solution and the solid drug moving towards the 
interior. Obviously, for this system to be diffusion controlled, the rate of 
dissolution of drug particles with in the matrix must be much faster than the 
diffusion rate of dissolved drug leaving the matrix. 
 Hydrophilic matrix tablets contain a water swellable polymer. On contact 
with gastric juices the tablet surface gels, impeding further liquid penetration into 
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the tablet core and providing a rate controlling layer. Dissolution occurs at the gel 
core interface and drug diffuse out through the gelled layer. 
 Drug release is controlled by penetration of water through a gel layer 
produced by hydration of the polymer and diffusion of drug through the swollen, 
hydrated matrix, in addition to erosion. The extent to which diffusion or erosion 
controls release depends on the polymerration. 
 Mechanism of release from erodible matrix has been described by 
Hopfenberg. A simple expression describing release from erodible is 
   [1 – Mt / M]1/3 = 1-kt  
  Where,  
Mt  =  mass of drug release at time t, 
    M  =  mass release at the infinite time, 
     K  =  rate of erosion, 
     t  =  time 
  
Thus a plot of [1 – Mt / M]1/3 versus the time will be linear. If the release 
of drug from the matrix is erosion controlled. 
 In order to ascertain whether the drug release occurs by diffusion or 
erosion, the drug release data was subjected to following modes of data 
treatments. 
 
1) Amount of drug release versus square root of time (Higuchi Plot). 
2) [1 – Mt / M]1/3 versus time. 
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Incorporation of Selected Formulation into Gel Base 
Selected phytosomal formulation were incorporated into Sodium alginate Gel 
base to form a gel. And it is evaluated the following parameters against marketed 
thuja gel(MTG)[6]. 
 pH 
 Viscosity 
 Drug content analysis 
 Spreadability 
 Extrudability 
 
pH 
 pH of the formulations were measured by using a digital type pH meter 
(Elico Make) by dipping the electrode completely in the Phytosomal Thuja 
gel(PTG) and Marketed Thuja Gel(MTG) so as to cover the electrode and read out 
the pH[8]. 
Viscosity 
 The viscosity of the prepared PTG and MTG was measured using 
Brookfield viscometer (R V 1 Brookfield Viscometer) at a controlled temperature. 
Drug content 
 A specific quantity (1.0gm) of PTG formulation and MTG formulation 
was dissolved in distilled water and the solution is filtered through the Whatman 
filter paper.  The absorbance of the solution was measured by UV 
spectrophotometer (Shimadzu 1700) at 361nm against blank[8]. 
Spreadability 
 One of the criteria for a gel to meet ideal quality is that it should possess 
good spreadability.  Adout 1gm of Phytosomal Thuja Gel(PTG)and Marketed 
Thuja Gel (MTG) was weighed and kept at the center of the glass plate (10×10 
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cm) and another glass plate is placed over it carefully, 2 kg weight was placed at 
the center of the plate (avoid sliding of the gel).  The diameter of the gel in cms, 
after 30 minutes was measured[8]. The spreadability was calculated by using the 
formula 
          Weight tied to the upper side X length of the glass slides 
Spreadability    =      -------------------------------------------------------------------- 
                        Time taken in seconds 
Tube extrudability 
 It is a useful empirical test to measure the force required to extrude the 
material from a tube.  The formulation under study was filled in a tube with nasal 
tip of 5 mm opening tube extrudability was then determined by measuring the 
amount of gel extruded through the tip when a pressure was applied on the tube 
gel. 
Invitro Drug Release studies  
Cellophane Membrane Treatment 
Cellophane membrane was boiled in the distilled water for 1 hr and 
washed with fresh distilled water for three times and kept in ethanol for 24 hrs.  It 
was washed with distilled water and treated with 0.3% sodium sulphite and 
soaked in distilled water for 2 min at 60◦C followed by acidified with 0.2% 
sulphuric acid. Finally the membrane was dipped in boric buffer (pH 9) till it is 
used for permeation study. 
Drug Permeation Studies 
 The in vitro release rate of PTG and MTG were evaluated by open ended 
tube through the cellophane membrane method using Phosphate Buffer pH 6.8 as 
diffusion medium up to 12 hours studies.  The cellophane membrane is tided in 
one end of the tube and then immersed in the receptor compartment containing 
400ml of Phosphate Buffer pH 6.8.  Which was stirred at medium speed and 
Evaluations  
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maintained at 37◦C ± 2◦C. Sample were withdrawn at regular time intervals and 
the same volume was replaced by fresh diffusion medium.  The samples were 
analyzed using UV – visible spectrophotometer (Shimadzu UV 1700) set at 
361nm 
Skin irritation Studies  
 Skin irritation test was performed on 3 rabbits weighing between 2 – 3.5 
kg.  Placebo gel was used as control. The Thuja occidentalis Phytosome loaded 
gel was used as a test sample.  Test was conducted unbraided skin of rabbits.  The 
control  was placed on left dorsal surface of each rabbit, whereas test formulation 
were placed on identical side of the right dorsal surface of the rabbits, the gel 
formulation were removed after 24 hours with the help of an alcohol swab and 
skin was examined for erythma/oedema[9].  
Stability Testing 
 Nowadays, Stability testing has become an integral part of formulation 
development. It generates information on which proposal for shelf life of drug or 
dosage form and their recommended storage conditions are based. 
Definition 
 Stability of a pharmaceutical preparation can be defined as “the capability 
of a particular formulation (dosage form or drug product) in a specific 
container/closure system to remain within its physical, chemical, microbiological, 
therapeutic and toxicological specifications throughout its shelf life[9].  
Purpose of Stability Testing 
 To ensure efficacy, safety and quality of active drug substances and dosage 
forms, 
 To establish shelf life or expiration period and to support label claims. 
 
Results and Discussion  
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CHAPTER-5 
RESULTS AND DISCUSSION 
 
Phytochemical Analysis 
Phytochemical analysis for Alkaloids 
S.No Test for Constituents Observation Inference 
1 Extract + Mayer’s reagent Cream precipitate Presence of 
Alkaloids 
2 Extract + Dragondarffs 
reagent 
Orange precipitate Presence of 
Alkaloids 
 
Table-15 
 
Phytochemical analysis for Corbohydrates 
S.No Test for Constituents Observation Inference 
1 Molisch Test;             
Extract Filtrate + 3 drops 
of alcoholic α- Napthol + 
2 ml Sulphuric acid 
 
Violet colour ring  
formed 
Presence of 
Corbohydrate 
2 Fehling’s Test; 
Extract Filtrate + 1ml 
Fehling’s reagent and 
heated 
Reddish Orange 
precipitate 
Presence of 
Corbohydrate 
 
     Table-16 
 
 
Results and Discussion  
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Phytochemical analysis of Glycoside 
S.No Test for Constituents Observation Inference 
1 Borntrager’s Test; 
             Extract filtrate + 
Chloroform added and 
then chloroform layer  is 
separated, then added 
dilute ammonia solution  
No colour change Presence of glycoside 
 
Table-17 
 
Phytochemical analysis of Phytosterol 
S.No Test for Constituents Observation Inference 
1 1 g of Extract + Dil. 
Acetic acid + Few drops  
of Con.Sulphuric acid 
Bluish green colour Absence of 
phytosterols 
 
Table-18 
Phytochemical analysis of  Fixed oil and Fat 
S.No Test for Constituents Observation Inference 
1 Extract placed in between 
two filter paper 
Oil stain in the filter 
paper 
Presence of oil and fat
 
Table-19 
Test for Tannin and Phenolic Compound 
S.No Test for Constituents Observation Inference 
1 Extract is treated with 10% 
lead acetate solution 
White precipitate is 
formed 
Presence of phenolic 
compounds 
 
Table-20 
Results and Discussion  
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Phytochemical analysis of Saponin 
S.No Test for Constituents Observation Inference 
1  Extract diluted with 20 ml of 
distilled water and agitated 
on a cylinder for 15 mts 
Formation of foam Presence of saponin 
Table-21 
 
 
   Phytochemical analysis of Flavonoids 
 
S.No Test for Constituents Observation Inference 
1 Shimoda’s Test              
Extract + Magnesium 
turnings + Few drops of 
Con.Hydro chloric acid and 
boil for 5 minutes 
Red colour is obtained Confirm the Presence 
of Flavonoids 
     Table-22 
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CHARACTERIZATION OF EXTRACT 
FT-IR of Extract 
  
Figure-6-a 
 
Interpretation of Extract 
S.No Wavelengh Functional Group 
1 3415 N-H Stretching 
2 2935 C-H Stretching 
3 2348 Broad OH 
4 1612 N-H Bending (primary amine) 
5 1415 CH3-O-R 
6 1270 C-O Stretching 
7 1063 C-N Stretching 
8 662 C-H Out of plane bond 
 
Table-23 
FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: K-E.sp 
Date: 1/7/2012
K-E.pk
K-E.sp  1801  4000.00  400.00  39.87  100.00  4.00  %T  10  0.50
REF 4000 86.26 2000 84.93 600
3919.29  83.34   3789.39  78.13   3415.62  39.87   2935.36  63.83   2348.64  75.56   
1612.66  66.47   1415.34  72.10   1270.65  77.69   1063.28  65.87   662.68   76.75   
4000.0 3000 2000 1500 1000 400.0
0.0
10
20
30
40
50
60
70
80
90
100.0
cm-1
%T 
3919.29
3789.39
3415.62
2935.36
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1612.66
1415.34
1270.65
1063.28
662.68
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 Absorption  Maxima 
Absorption maxima of Extract 
 
 
Figure-7 
  
 The drug solution (1mg/ml) in phosphate buffer pH 6.8 was taken in the 
cuvette scanned in the range of 230 to 400 nm in a UV spectrophotometer.  It 
exhibits maxima at 361nm.  Therefore, all the further measurements were taken at 
361nm 
    Solubility profile of Extract 
 S.No Solvent Solubility 
1 Distilled water Very soluble 
2 PBS (pH 6.8) Very soluble 
3 Methanol Sparingly soluble 
4 Ethanol Soluble 
5 Chloroform practically insoluble 
6 Acetone Practically insoluble 
 
Table-24 
Results and Discussion  
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    Standard Curve in PBS 6.8 
S.No Concentration 
(µg/ml) 
Absorbance 
at 361nm 
1 0 0 
2 10 0.1843 
3 20 0.3662 
4 30 0.4882 
5 40 0.6442 
6 50 0.8344 
7 60 0.9611 
 
Table-25 
     
    Standard curve of Extract 
 
Figure- 8 
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Compatibility studies 
 
   FT-IR Spectrum of Thuja occidentalis 
    
 
     Figure-9  
 
FT-IR Interpretation of Thuja occidentalis 
S.No Wavelengh Functional Group 
1 3415 N-H Stretching 
2 2935 C-H Stretching 
3 2348 Broad OH 
4 1612 N-H Bending (primary amine) 
5 1415 CH3-O-R 
6 1270 C-O Stretching 
7 1063 C-N Stretching 
8 662 C-H Out of plane bend 
 
Table-26 
FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: K-E.sp 
Date: 1/7/2012
K-E.pk
K-E.sp  1801  4000.00  400.00  39.87  100.00  4.00  %T  10  0.50
REF 4000 86.26 2000 84.93 600
3919.29  83.34   3789.39  78.13   3415.62  39.87   2935.36  63.83   2348.64  75.56   
1612.66  66.47   1415.34  72.10   1270.65  77.69   1063.28  65.87   662.68   76.75   
4000.0 3000 2000 1500 1000 400.0
0.0
10
20
30
40
50
60
70
80
90
100.0
cm-1
%T 
3919.29
3789.39
3415.62
2935.36
2348.64
1612.66
1415.34
1270.65
1063.28
662.68
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FT-IR Spectrum of Cholesterol 
   
Figure-10 
 
   FT-IR Interpretation of Cholesterol 
 
Table-27 
 
 
S.No Wave lengh Functional Group 
1 3422.36 O-H Stretching 
2 2936.18 C-H Stretching 
3 1710.46 C=O Stretching 
4 1353.20-1463.18 C=N Stretching 
5 1593.50 C=O Stretching 
6 1226.10 C-O Stretching 
7 1055.83 C-C Stretching 
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FT-IR Spectrum of Chloroform 
 
Figure-12 
  
FT-IR Interpretation of Chloroform 
S.No Wavelengh Functional Group 
1 3424.62 O-H Stretching 
2 1592.25 C=O Stretching 
3 668.34 C-H Out of plane bend 
4 1485 C-H Bending 
5 1349.20 C-N Stretching 
 
Table-29 
 
 
FTIR SPECTRUM
ACIC
St.Joseph's College ( Autonomous )
Trichy-2
Spectrum Name: PCPS-Chcl3.sp 
Date: 3/17/2012
PCPS-Chcl3.pk
PCPS-C~1.SP  1801  4000.00  400.00  19.02  100.00  4.00  %T  15  1.00
REF 4000 88.18 2000 65.24 600
3920.03  79.63   3794.80  67.42   3407.02  19.02   1624.99  64.78   1388.57  77.19   
1219.43  66.35   1030.31  73.28   771.00   31.61   673.84   79.53   
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3920.03
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3407.02
1624.99
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771.00
673.84
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FT-IR Spectrum of Methanol 
 
Figure-13 
 
  FT-IR Interpretation of Methanol 
S.No Wavelengh Functional Group 
1 3415 N-H Stretching 
2 2935 C-H Stretching 
3 2348S Broad OH 
4 1612 N-H Bending (primary amine) 
5 1415 CH3-O-R 
6 1270 C-O Stretching 
7 1063 C-N Stretching 
8 662 C-H Out of plane bend 
 
    Table-30 
 
FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: PCPS-M.sp 
Date: 3/17/2012
PCPS-M.pk
PCPS-M.sp  1801  4000.00  400.00  3.19  99.83  4.00  %T  15  1.00
REF 4000 99.65 2000 95.81 600
3391.46  3.19   2952.52  22.38  2841.09  37.67  2526.11  88.05  2049.41  91.01  
1650.36  66.38  1414.44  64.84  1026.12  17.79  677.29   62.75  
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FT-IR Spectrum of Formulation (Placebo) 
 
 
    Figure-14 
FT-IR Interpretation of Formulation (Placebo) 
 
S.No Wavelengh Functional Group 
1 3563 N-H Stretching 
2 2876 C-H Stretching 
3 2186 Broad OH 
4 1684 N-H Bending (primary amine) 
5 1380 CH3-O-R 
6 1265 C-O Stretching 
7 1040 C-N Stretching 
8 842 C-H Out of plane bend 
 
    Table-31 
 
FTIR SPECTRUM
ACIC
St.Joseph's College ( Autonomous )
Trichy-2
Spectrum Name: PCPS-Placebo.sp 
Date: 3/17/2012
PCPS-Placebo.pk
PCPS-P~1.SP  1801  4000.00  400.00  3.32  99.02  4.00  %T  15  1.00
REF 4000 98.94 2000 92.28 600
3940.27  97.19  3453.04  3.32   2947.90  15.88  2530.79  60.57  2222.18  84.77  
2045.22  82.03  1725.91  51.32  1657.92  55.26  1446.65  40.56  1228.94  48.36  
1032.75  42.12  756.63   52.16  
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FT-IR Spectrum of Formulation 
 
    Figure-15 
 
FT-IR- Interpretation of Formulation 
 
S.No Wavelengh Functional Group 
1 3540 N-H Stretching 
2 2852 C-H Stretching 
3 2490 Broad OH 
4 1464 N-H Bending (primary amine) 
5 1280 CH3-O-R 
6 1184 C-O Stretching 
7 980 C-N Stretching 
8 648 C-H Out of plane bend 
    
Table-32 
FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: PCPS-Formulation.sp 
Date: 3/17/2012
PCPS-Formulation.pk
PCPS-F~1.SP  1801  4000.00  400.00  3.17  99.61  4.00  %T  15  1.00
REF 4000 96.67 2000 83.28 600
3920.51  87.28  3790.06  76.51  3390.97  3.17   2937.20  3.70   2227.00  69.84  
2044.37  71.15  1717.85  30.76  1649.55  33.28  1447.48  16.54  1227.17  20.87  
1030.17  9.85   757.09   14.13  
4000.0 3000 2000 1500 1000 400.0
0.0
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SEM Photography of Phytosome DDS 
 
 
Figure-16 
Shape of Thuja occidentalis Phytosome DDS 
 
 
Figure-17 
Results and Discussion  
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Particle size distribution of Phytosomes  
 
S.No Formulation Code Average Particle Size Of 
phytosome(nm) 
1 F1 260 
2 F2 100 
3 F3 60 
 
Table-33 
 
  Comparitive Chart of Average Particle Size  
 
 
Figure-18 
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Drug content 
 
S.No Formulation Code % Drug content 
1 F1 64 ± 0.5 
2 F2 78 ± 0.5 
3 F3 67 ± 0.5 
 
Table-34 
 
 
 
Comparative Drug Content 
 
Figure-19 
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Drug entrapment efficiency 
 
S.No Formulation Code % Entrapment efficiency 
1 F1 64 ± 0.5 
2 F2 82 ± 0.5 
3 F3 76 ± 0.5 
 
Table-35 
 
Comparison of Drug entrapment efficiency 
  
 
Figure-20 
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IN VITRO DRUG RELEASE STUDIES 
 
Invitro drug Release F1 
 
S.No Time Absorbance Concentration Amount present % Amount release
1 15 0.0821 3.02580 1.2103 5.1032 
2 30 0.1072 4.64516 1.8580 8.5806 
3 45 0.1172 5.29032 2.1161 12.1612 
4 60 0.1387 6.67741 2.6709 15.7096 
5 90 0.1683 8.58709 3.4348 18.3486 
6 120 0.1836 9.57419 3.8296 21.2967 
7 150 0.2018 10.7483 4.2993 23.9935 
8 180 0.2159 11.6580 4.6632 27.6322 
9 240 0.2216 12.0258 4.8103 28.1032 
10 300 0.2318 12.6838 5.0735 30.7354 
11 360 0.2337 12.8064 5.1225 32.2258 
12 420 0.2379 13.0774 5.2309 38.3096 
13 480 0.2391 13.1548 5.2619 41.6193 
14 540 0.2476 13.7032 5.4812 46.8129 
15 600 0.2498 13.8451 5.5380 55.3806 
16 660 0.2661 14.8967 5.9587 54.5871 
17 720 0.2373 14.9741 5.9896 51.8967 
 
Table-36 
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Invitro drug Release F1 
 
 
    Figure-21 
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Invitro drug release F2 
 
S.No Time Absorbance Conc Amt Release %Amt Release 
1 15 0.0736 2.477419 0.9909 9.9096 
2 30 0.0926 3.7032 1.4818 14.8167 
3 45 0.1011 4.2516 1.7006 17.0064 
4 60 0.1026 4.3483 1.7393 17.3935 
5 90 0.1382 6.6451 2.6580 26.5806 
6 120 0.1511 7.4774 2.9909 29.9096 
7 150 0.1629 8.2386 3.2954 32.9548 
8 180 0.1631 8.2516 3.3006 33.0064 
9 240 0.1821 9.4774 3.7909 37.9096 
10 300 0.2349 12.8834 5.1535 51.5354 
11 360 0.2481 13.7354 5.4941 54.9419 
12 420 0.2482 13.7419 5.4964 54.9677 
13 480 0.2693 15.1032 6.0412 63.4129 
14 540 0.2769 15.5935 6.2374 63.3741 
15 600 0.2839 16.0451 6.4180 64.1806 
16 660 0.2841 16.0580 6.4232 64.23226 
17 720 0.2681 15.0258 6.0103 60.10323 
 
Table-37 
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Invitro drug release F2 
 
Figure-22 
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Invitro drug release F3 
 
S.No Time Absorbance Concentration Amount Release %Amt Release
1 15 0.0683 2.135484 0.854194 8.541935 
2 30 0.1038 4.425806 1.770323 17.70323 
3 45 0.1095 4.793548 1.917419 19.17419 
4 60 0.1385 6.664516 2.665806 21.65806 
5 90 0.1567 7.83871 3.135484 22.35484 
6 120 0.1923 10.13548 4.054194 24.54194 
7 150 0.2009 10.69032 4.276129 26.76129 
8 180 0.2154 11.62581 4.650323 26.50323 
9 240 0.2211 11.99355 4.797419 28.97419 
10 300 0.2318 12.68387 5.073548 30.73548 
11 360 0.2314 12.65806 5.063226 32.63226 
12 420 0.2371 13.02581 5.210323 38.10323 
13 480 0.2411 13.28387 5.313548 40.13548 
14 540 0.2471 13.67097 5.468387 41.68387 
15 600 0.2485 13.76129 5.504516 50.04516 
16 660 0.2716 15.25161 6.100645 53.00645 
17 720 0.266 14.89032 5.956129 52.56129 
 
Table-38 
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Invitro Drug Release of F 3 
 
  
Figure-23 
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Comparative Invitro Drug Release profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table-39 
 
 
S.No Time F1 F2 F3 
1 15 5.1032 9.9096 8.541935 
2 30 8.5806 14.8167 17.70323 
3 45 12.1612 17.0064 19.17419 
4 60 15.7096 17.3935 21.65806 
5 90 18.3486 26.5806 22.35484 
6 120 21.2967 29.9096 24.54194 
7 150 23.9935 32.9548 26.76129 
8 180 27.6322 33.0064 26.50323 
9 240 28.1032 37.9096 28.97419 
10 300 30.7354 51.5354 30.73548 
11 360 32.2258 54.9419 32.63226 
12 420 38.3096 54.9677 38.10323 
13 480 41.6193 63.4129 40.13548 
14 540 46.8129 63.3741 41.68387 
15 600 55.3806 64.1806 50.04516 
16 660 54.5871 64.23226 53.00645 
17 720 51.8967 60.10323 52.56129 
Results and Discussion  
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Comparative Invitro Drug Release profile 
 
 
Figure - 24 
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Release Kinetics 
Table- Parameters of the model equations applied to the release of Thuja 
occidentalis Phytosomal formulation for Topical administration 
Release Kinetics of Formulation 
 
Formulation Model r2 Slope K 
F1 Zero order equation 0.9708 1.6908 4.6247 
 First order equation 0.9690 -0.0184 2.0507 
 Higuchi model 0.9735 14.536 -18.61 
 Hixson-Crowell 0.770 0.058 -1.797 
 Modified cube root 0.4462 2.054 -35.30 
 Korsmeyer-peppas 0.964 0.864 1.474 
     
F2 Zero order equation 0.994 0.8764 5.1956 
 First order equation 0.9598 -0.0076 2.013 
 Higuchi model 0.9739 9.5195 -12.656 
 Hixson-Crowell 0.803 0.031 -1.818 
 Modified cube root 0.9584 5.330 -18.18 
 Korsmeyer-peppas 0.986 0.753 1.58 
     
F3 Zero order equation 0.8671 4.773 -1.6277 
 First order equation 0.9137 -0.0184 2.2060 
 Higuchi model 0.939 25.83 -31.00 
 Hixson-Crowell 0.8396 0.279 -0.167 
 Modified cube root 0.8089 0.946 -0.9066 
 Korsmeyer-peppas 0.750 0.785 1.291 
 
Table-40 
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Release kinetics of F1, F2, F3 
Release Kinetics of F1 
 
Figure - 25 
 
 
Figure – 26 
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Figure - 27 
 
 
Figure - 28 
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Release kinetics of F2 
 
 
Figure - 29 
 
 
Figure - 30 
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Figure - 31 
 
 
Figure - 32 
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Release Kinetics of F3 
 
 
Figure – 33 
 
 
Figure - 34 
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Figure - 35 
 
Figure - 36 
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Evaluation Parameters of Gel 
 
Formulation 
code 
pH Viscosity 
Centipoises 
(Cps) 
Drug 
Content 
(%) 
Spreadability 
Centimeters 
(Cm) 
Extrudability 
PTG 6.8 4200 86 7.2 E 
MTG 6.9 42000 72 7.6 E 
 
Table-41 
Invitro Drug release profile of PTG 
S.No Time Absorbance Conc Amt Release %Amt Release 
1 15 0.0623 1.748387 0.699355 6.993548 
2 30 0.0814 2.980645 1.192258 11.92258 
3 45 0.1011 4.251613 1.700645 17.00645 
4 60 0.1126 4.993548 1.997419 19.97419 
5 90 0.1391 6.703226 2.68129 26.8129 
6 120 0.1681 8.574194 3.429677 34.29677 
7 150 0.1879 9.851613 3.940645 39.40645 
8 180 0.2014 10.72258 4.289032 42.89032 
9 240 0.2201 11.92903 4.771613 47.71613 
10 300 0.2349 12.88387 5.153548 51.53548 
11 360 0.2414 13.30323 5.32129 53.2129 
12 420 0.2479 13.72258 5.489032 54.89032 
13 480 0.2591 14.44516 5.778065 57.78065 
14 540 0.2683 15.03871 6.015484 60.15484 
15 600 0.2767 15.58065 6.232258 62.32258 
16 660 0.2799 15.7871 6.314839 63.14839 
17 720 0.2679 15.0129 6.005161 60.05161 
 
Table-42 
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Invitro Drug Release of PTG 
  
Figure-37 
 
   Invitro Drug Release Profile of MTG 
S.No Time Absorbance Conc Amt Release %Amt Release
1 15 0.0971 3.993548 1.597419 15.97419 
2 30 0.1371 6.574194 2.629677 26.29677 
3 45 0.1571 7.864516 3.145806 31.45806 
4 60 0.1936 10.21935 4.087742 40.87742 
5 90 0.2361 12.96129 5.184516 51.84516 
6 120 0.2671 14.96129 5.984516 59.84516 
7 150 0.2891 16.38065 6.552258 65.52258 
8 180 0.2988 17.00645 6.802581 68.02581 
9 240 0.2532 14.06452 5.625806 56.25806 
10 300 0.2053 10.97419 4.389677 43.89677 
11 360 0.1783 9.232258 3.692903 36.92903 
12 420 0.0836 3.122581 1.249032 12.49032 
13 480 0.0471 0.767742 0.307097 3.070968 
14 540 0.0036 -2.03871 -0.81548 -8.15484 
15 600 0.0018 -2.15484 -0.86194 -8.61935 
 
Table-43 
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Invitro Drug Release Profile of MTG 
  
Figure-38 
Comparative % Drug Release Profile of PTG and MTG 
S.No Time PTG MTG 
1 15 6.993548 15.97419 
2 30 11.92258 26.29677 
3 45 17.00645 31.45806 
4 60 19.97419 40.87742 
5 90 26.8129 51.84516 
6 120 34.29677 59.84516 
7 150 39.40645 65.52258 
8 180 42.89032 68.02581 
9 240 47.71613 56.25806 
10 300 51.53548 43.89677 
11 360 53.2129 36.92903 
12 420 54.89032 12.49032 
13 480 57.78065 3.070968 
14 540 60.15484 -8.15484 
15 600 62.32258 -8.61935 
16 660 63.14839  
17 720 60.05161  
Table-44 
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Comparative Drug Release profile of PTG and MTG 
 
 
Figure-39 
 
 
Skin Irritation Studies 
    Skin Irritation Results 
Formulation Skin irritation 
Placebo Gel - 
Phytosome Gel - 
 
+ indicate edema, - indicate no edema 
        Table-45 
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Preparation of Skin irritation test 
 
 
     Figure-40 
After 24 hours study with Phytosome loaded Gel base 
   
       Figure-41 
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After 24 hours study with Placebo Gel base 
 
 
Figure- 42 
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   Effect on storage on particle size 
S.No 
 
 
Time intervals Particle Size(nm) 
 
Storage Conditions 
 
40◦C±2◦C RH 70% 
 
Room Temperature 
 
1 
 
Initial 
 
120 
 
118 
 
2 
 
After 1 month 
 
108 
 
106 
 
3 
 
After 2 month 
 
117 
 
110 
 
4 
 
After 3 month 
 
125 
 
118 
      
Table –46 
 
  Effect of Storage on Percentage Drug loading 
S.No 
 
 
Time intervals  
Percentage Drug Loading 
 
Storage Conditions 
 
40◦C±2◦C RH 70% 
 
Room Temperature 
 
1 
 
Initial 
 
64±0.5 
 
62±0.5 
 
2 
 
After 1 month 
 
58.5±0.26 
 
60.5±0.36 
 
3 
 
After 2 month 
 
54.5±1.24 
 
58.5±1.04 
 
4 
 
After 3 month 
 
52.5±1.06 
 
56.5±1.01 
     
Table-47 
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Effect Storage on Percentage Drug Content 
 
S.No 
 
 
Time Intervals  
Percentage Drug Content 
Storage Conditions 
 
40◦C±2◦C RH 70% 
 
Room Temperature 
 
1 
 
Initial 
 
78 
 
78 
 
2 
 
After 1 month 
 
73.5 
 
75.6 
 
3 
 
After 2 month 
 
63.5 
 
73.5 
 
4 
 
After 3 month 
 
58.72 
 
71.62 
 
Table-48 
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Effect of Storage on Physical Stability 
 
S.No 
 
Parameters 
 
40◦C±2◦CRH 70%
 
Room 
Temperature 
1 Visual appearance 
Initial Cloudy Cloudy 
1st  month Cloudy Cloudy 
2nd month Cloudy Cloudy 
3rd month Cloudy Cloudy 
2 Shape 
Initial Spherical Spherical 
1st  month Spherical Spherical 
2nd month Spherical Spherical 
3rd month Spherical Spherical 
3 pH 
Initial 6.8 6.8 
1st  month 6.8 6.8 
2nd month 6.8 6.8 
3rd month 6.8 6.8 
4 Phase separation 
Initial Not found Not found 
1st  month Not found Not found 
2nd month Not found Not found 
3rd month Not found Not found 
5 Leakage 
Initial Not found Not found 
1st  month Not found Not found 
2nd month Found Not found 
3rd month Found Not found 
6 Odor   
 Initial Odorless Odorless 
 1st  month Odorless Odorless 
 2nd month Odorless Odorless 
 3rd month Odorless Odorless 
 
Table-49 
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RESULTS AND DISCUSSION 
 The Phytosomal preparation of Thuja occidentalis were prepared by Thin 
Film Hydration Technique using Rotary Flask Evaporation method. 
 The collected plant Thuja occidentalis was authenticated by Prof. 
P.Jayaraman, Director, Institute of Herbal Botany, Plant Anatomy Research 
Centre, Chennai. Then it was subjected to Drying and powder formation for 
Soxylation method using Soxhlet apparatus. 
 Based on the literature survey, the solvent Pet ether and Ethanol were 
selected for extraction. 
 The crude ethanolic extract of Thuja occidentalis was investigated for 
phytoconstituent identification. It confirms the presence of Corbohydrate, 
Alkaloid, Glycoside, Saponins, Fixed oil, Fats and Flavonoids. 
 Also phytochemical analysis confirms the absence of Phytosterol. 
 The major constituent of extract containing flavonoids was confirmed by 
taking absorption maxima in UV spectrometer using phosphate buffer 6.8 as 
solvent. It showed absorption maxima at 361nm. This was compared with 
reference standard of Thuja occidentalis constituent of flavonoid like quercetin 
showing the maximum absorption peak at 364 nm in the phosphate buffer 6.8 
solution. This confirms the  presence of  Flavonoids in the crude extract. 
 The various formulation and process variables were optimized to get small 
spherical shaped vesicles with high Drug entrapment efficiency. The results are as 
follows: 
 Phosphotidyl choline and Cholesterol were used to achieve maximum drug 
encapsulation. The amount of phosphotidyl choline and cholesterol has an effect 
on the preparations of  phytosome. 
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 When the concentration of lecithin and cholesterol is too low, the DEE is 
also very low. 
 The various concentration of phosphatidyl choline were used to access the 
effect on the formulation characteristic from 1 to 3 ratios i.e by increasing the 
concentration from 40mg to 60 mg. 
 Increase in the concentration of phosphatidyl choline leads to more 
number of phytosomal dispersion, resulting in to an increased % drug entrapment. 
 However, Further increase in the phosphatidyl choline concentration has 
no proportionate increase in % drug entrapment due to large surface occupied by 
phophatidyl choline layer and also may be due to system saturation approaching.   
 When the concentration of phosphatidyl choline is too high, the DEE is 
very low and the release of the drug from vesicle is also affected i.e 1:1.5:6 
(Drug:Cholesterol:Phosphotidyl choline).   
 By increasing the phospholipid to optimum concentration  i.e 1:1.5:5  
(Drug:Cholesterol:Phosphotidyl choline)  the particle size decreases from 300 nm 
to 100nm and the entrapment efficiency was also increased from 64% to 82%. 
 Thus the optimized ratio of Cholesterol & Phosphatidyl choline to Drug 
was 1:1.5:5 
 At medium speed of (100±5rpm)  The Phytosomes  produced were of 
desired size range with maximum encapsulation efficiency. At low speed (50±5 
rpm) it forms clumps and not uniform and larger size with low encapsulation 
efficiency. Which at high speed (above 100 rpm) the particles are irregular shaped 
with less encapsulation efficiency. 
 The temperature during phytosomal formulation was optimized. At the 
temperature of  60 C±2 C, spherical vesicles are formed.  At high temperature 
above 100 C, those formed vesicles are less and irregular. At temperature below60 
C, irregular shaped vesicles are formed. 
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 Ultrasonication time was also optimized to get small spherical vesicles. At 
10 minutes incomplete and large irregular shaped vesicles with high encapsulation 
efficiency was obtained and further increase in sonication time resulted in to 
reduction in % drug entrapment. The decrease in drug entrapment due to leakage 
of drug during sonication. Thus at 30 minutes, the vesicles are broken with 
leakage of drug and low encapsulation efficiency. Hence sonication time was 
optimized to 15 minutes and further reduction in size by increasing sonication 
time was not attempted. 
 During ultrasonication, the temperature maintenance was also optimized. 
At the temperature of 10 C to 20 C numerous vesicles of moderate size are 
formed. At low temperature 5 C to 10 C, the size of vesicle are decreases. While 
room temperature large sized vesicles was formed. 
 The effect of hydration liquid on drug entrapment efficiency was 
optimized. When the usage of water as a hydration liquid, the entrapment 
efficiency is high. While at the usage of 0.1M HCL, the DEE is very low. But 
DEE is achieved minimally by usage of PBS 6.8 as hydration liquid. 
 The morphological studies were performed by SEM, Showed uniform 
shape, discreate particle without aggregation and smooth in surface morphology 
with size range of 50nm-300nm 
 IR studies indicated that the extract of Thuja occidentalis was dispersed in 
molecular level. The IR spectrum of Thuja occidentalis showed sharp peaks. 
However the sharp peaks were disappeared in Thuja occidentalis loaded 
phytosomal formulation, it may be due to the drug can be existed as a molecular 
dispersion and similar functional groups and structure may broaden the peaks in 
phytosomal formulation. 
 There are no extra peaks seen other than the normal peak in the spectra of 
the Thuja occidentalis loaded Phytosomal formulation and so there is no 
interaction with the drug and Excipients, it confirms that they are compatible with 
each other.  
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 The IR spectra of the extract and excipients combination were compared 
with the spectra of the crude extract and individual excipients in which no shifting 
of peaks was significantly found, indicating the stability of the drug during 
encapsulation process. 
 The invitro release profile of phytosomal formulation of Thuja 
occidentalis are F1, F2, F3 were shown in Figure-24 and Table-39. 
 The release behavior of Drug from the Phytosomal formulation exhibited a 
biphasic pattern, that is characterized by faster onset of action and slower 
sustained release. 
 The Formulation F2 containing the ratios of 1:1.5:5 
(Drug:Cholesterol:Phosphotidyl choline) showed the drug release of 64% at 11 
hours. F1 showed the release of 54% at 11 hours and, F3 showed 53% release at 11 
hours.  An initial burst drug release was observed up to 6 hours and there is a 
constant drug release was observed up to 12 hours. 
 The initial burst release may be due to the drug present in the surfacial 
drug on the surface of Phytosome. 
 The data obtained from In-vitro release profile after 12 hours was fitted 
with various kinetic equations to determine the mechanism of drug release and 
release rate as indicated by higher correlation coefficients(r2). The drug release 
from phytosomal formulation follows zero order and non-fickian diffusion.  
 These findings indicates that the drug release from the formulated 
Phytosome were diffusion controlled 
 To confirm the release mechanism, the data of first 60% release were 
applied to Korsmeyer peppas equation to find out the release exponent ‘n’, which  
indicates the mechanism of drug drug diffusion from the phytosomal formulation. 
The data were fitted with equation as indicated by higher correlation 
coefficients(r2) and mechanism was found to be non-fickian diffusion (anomalous 
transport). 
Results and Discussion  
 
‐147‐ 
 
 Cumulative % drug release was analyzed using PRISM software. The 
kinetic data of F2 formulation was best fitted to Korsmeyer and Peppa’s model 
and the value of regression co efficient, r = 0.994  and n = 0.925 which follows 
non-fickian, Super case-II transport. 
  For the best formulation F2 were subjected to skin irritation studies and  
stability studies at 40 C/ 75% RH up to 3 months. The potency Phytosome  under 
accelerated stability conditions were within 90% to 110% of the label claim. 
Overall, results from the stability studies indicated that the beads were chemically 
stable for more than 3 months. 
Skin irritation studies; 
 Skin irritation property of Phytosomal Thuja occidentalis Gel (PTG) is 
performed in rabbit animal model against placebo gel (PG) used as a control. 
 After 24 hours of application the surface of was cleaned with cotton swap 
and observed for allergic and hypersensitivity ( erythma and oedema) 
Stability Testing 
 The selected F2 formulation is incorporated in gel base and it is evaluated 
for its stability by using accelerated stability chamber (40◦C±2◦C RH 70%) and it 
is compared with  formulation stored in Room temperature. The results are shown 
in Table- 46,47,48,49. 
 The particle size analysis of PTG stored in AST chamber was evaluated at 
initial and at the end of 1st, 2nd, 3rd month, showing 118nm, 108nm, 117nm, 125nm  
respectively. Also the sample stored in room temperature was evaluated the for 
the same period showed 100nm, 106nm, 110nm, 118nm respectively. 
 No much differences was observed during this period on particle size, the 
formulations retains with its stability. 
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The drug loading property is also evaluated for initial and at the end of 1st, 
2nd, 3rd month of the sample stored in AST chamber showed 64%, 58.5%, 54.5%, 
52.5% respectively.  Also the sample stored in room temperature was evaluated 
the  for the same period showed 62%, 60.5%, 58.5%, 56.5% respectively. 
 The formulation PTG on storage of AST chamber, the drug loading 
capacity is reduced compared with the formulation stored in room temperature. 
This is due to leakage of the drug from the formulation.  
 The drug content analysis of AST chamber stored sample evaluated for the 
same period showed 78%, 73.5%, 63.5%, 58.7%  respectively. Also the sample 
stored in room temperature was evaluated the  for the same period showed 78%, 
75.65, 73.5%, 71.62% respectively. 
 On storage on AST chamber contained formulation PTG showed reduction 
in drug content in the formulation compared with the sample stored in room 
temperature. 
 The physical properties of sample analysed like, visual appearance, shape, 
pH, phase separation and odor. 
 No changes was observed during storage on physical properties of the 
AST chamber stored gel and sample stored in room temperature except the 
leakage of drug from the formulation occurred in the sample stored in AST 
chamber at the end of 2nd, 3rd months . It is stable up to the end of 1st month. 
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CONCLUSION 
 
 Phytosome are one of the novel colloidal drug delivery systems that could 
potentially carry out multiple tasks in a predefined sequences thus holds great 
promise for reaching the goal of controlled as well as site specific drug release 
from the vesicles across the biological membrane. 
 The specific properties of  Phytosome such as high stability, high carrier 
capacity, and sustained drug release up to 120 hours enable improvements of drug 
bioavailability and enhanced therapeutic effect, reduction of dosing frequency. 
And also reduced toxic side effect since the dose is reduced drastically to very 
lesser amount and it is delivered to target tissue. 
 Thuja occidentalis plant was collected and it is extracted and formulated to 
Phytosomal formulation by using cholesterol and phosphotidyl choline by thin 
film hydration technique with rotary flask evaporator. 
 Three different formulations (F1, F2, F3) were prepared and all of them 
subjected to various evaluations like particle size and shape, drug content, drug 
entrapment, invitro release studies, skin irritation studies and stability studies. 
 All among the formulation, F2 showed the optimum particle size range of 
100nm and spherical  in shape.  
 The drug content and drug entrapment of formulation F2 showed 78% and 
82% respectively. 
 The invitro release profile of formulated Phytosome were evaluated and 
the formulation F2 proved to be of great interest since it gives a required release 
of 64% for an extended period of time of 12 hours. 
 Further, from the release kinetic study it revealed that the drug diffusion 
follows zero order kinetics and non-fickian diffusion controlled (Higuchi). The 
selected formulation has proved the purpose as designed.  
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The skin irritation studies of Phytosome incorporated Thuja Gel(PTG) is 
evaluated against Placebo Gel, and there is no irritation symptoms like 
erythma/oedema 
 The selected formulation F2 was subjected to further studies and then  it is 
incorporated in to Phytosomal Thuja Gel (PTG) is showed more stability profile in 
room temperature compared to Gel stored in AST chamber. 
 From the results, it may conclude that the formulation F2 has achieved the 
objective of converting the crude extract in to a novel targeted drug delivery 
system as Phytosome to treat a medically challengeable disease Wart.     
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